<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName ACSJournal-v102.dtd?>
<?SourceDTD.Version 1.02?>
<?ConverterInfo.XSLTName acs2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">J Chem Inf Model</journal-id>
    <journal-id journal-id-type="iso-abbrev">J Chem Inf Model</journal-id>
    <journal-id journal-id-type="publisher-id">ci</journal-id>
    <journal-id journal-id-type="coden">jcisd8</journal-id>
    <journal-title-group>
      <journal-title>Journal of Chemical Information and Modeling</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1549-9596</issn>
    <issn pub-type="epub">1549-960X</issn>
    <publisher>
      <publisher-name>American Chemical
Society</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">7592117</article-id>
    <article-id pub-id-type="doi">10.1021/acs.jcim.0c00589</article-id>
    <article-categories>
      <subj-group>
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>PRosettaC: Rosetta Based Modeling of PROTAC Mediated
Ternary Complexes</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="ath1">
        <name>
          <surname>Zaidman</surname>
          <given-names>Daniel</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath2">
        <name>
          <surname>Prilusky</surname>
          <given-names>Jaime</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath3">
        <name>
          <surname>London</surname>
          <given-names>Nir</given-names>
        </name>
        <xref rid="cor1" ref-type="other">*</xref>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <aff id="aff1"><label>†</label>Department
of Organic Chemistry, <institution>The Weizmann Institute
of Science</institution>, 76100, Rehovot, <country>Israel</country></aff>
      <aff id="aff2"><label>‡</label>Life
Sciences Core Facilities, <institution>Weizmann Institute
of Science</institution>, 76100, Rehovot, <country>Israel</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>*</label>E-mail: <email>nir.london@weizmann.ac.il</email>.</corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>25</day>
      <month>09</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="ppub">
      <day>26</day>
      <month>10</month>
      <year>2020</year>
    </pub-date>
    <volume>60</volume>
    <issue>10</issue>
    <fpage>4894</fpage>
    <lpage>4903</lpage>
    <history>
      <date date-type="received">
        <day>27</day>
        <month>05</month>
        <year>2020</year>
      </date>
    </history>
    <permissions>
      <copyright-statement/>
      <copyright-year>2020</copyright-year>
      <copyright-holder>American Chemical Society</copyright-holder>
      <license>
        <license-p>This is an open access article published under a Creative Commons Attribution (CC-BY) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/page/policy/authorchoice_ccby_termsofuse.html">License</ext-link>, which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.</license-p>
      </license>
    </permissions>
    <abstract>
      <p content-type="toc-graphic">
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00589_0008" id="ab-tgr1"/>
      </p>
      <p>Proteolysis-targeting
chimeras (PROTACs), which induce degradation
by recruitment of an E3 ligase to a target protein, are gaining much
interest as a new pharmacological modality. However, designing PROTACs
is challenging. Formation of a ternary complex between the protein
target, the PROTAC, and the recruited E3 ligase is considered paramount
for successful degradation. A structural model of this ternary complex
could in principle inform rational PROTAC design. Unfortunately, only
a handful of structures are available for such complexes, necessitating
tools for their modeling. We developed a combined protocol for the
modeling of a ternary complex induced by a given PROTAC. Our protocol
alternates between sampling of the protein–protein interaction
space and the PROTAC molecule conformational space. Application of
this protocol—PRosettaC—to a benchmark of known PROTAC
ternary complexes results in near-native predictions, with often atomic
accuracy prediction of the protein chains, as well as the PROTAC binding
moieties. It allowed the modeling of a CRBN/BTK complex that recapitulated
experimental results for a series of PROTACs. PRosettaC generated
models may be used to design PROTACs for new targets, as well as improve
PROTACs for existing targets, potentially cutting down time and synthesis
efforts. To enable wide access to this protocol, we have made it available
through a web server (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://prosettac.weizmann.ac.il/">https://prosettac.weizmann.ac.il/</uri>).</p>
    </abstract>
    <custom-meta-group>
      <custom-meta>
        <meta-name>document-id-old-9</meta-name>
        <meta-value>ci0c00589</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>document-id-new-14</meta-name>
        <meta-value>ci0c00589</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>ccc-price</meta-name>
        <meta-value/>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="sec1">
    <title>Introduction</title>
    <p>Proteolysis-targeting
chimeras (PROTACs) are modular small molecules
that induce the degradation of a target protein.<sup><xref ref-type="bibr" rid="ref1">1</xref>−<xref ref-type="bibr" rid="ref3">3</xref></sup> PROTACs can
be conceptually divided into three parts: A target binding moiety,
an E3 ubiquitin-ligase binding moiety, and a linker that connects
the two. Through simultaneous binding of their target and E3 ligase,
they induce the formation of a ternary complex that facilitates the
ubiquitination of the target, which then leads to its proteasomal
degradation.</p>
    <p>PROTACs offer several advantages over traditional
small molecule
inhibitors. These include: a complete inhibition of function, which
is not limited to enzymatic function or a specific site on the target;
long duration-of-action that is proportional to the protein turnover
rate; and enhanced selectivity.<sup><xref ref-type="bibr" rid="ref4">4</xref>−<xref ref-type="bibr" rid="ref7">7</xref></sup> Finally, since a single PROTAC molecule can degrade
multiple copies of the target, PROTACs can work at a substoichiometric
concentration.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> These advantages propelled
wide interest in their development as chemical tools and potential
drugs.</p>
    <p>Most reported PROTACs to date are based on a known and
potent small-molecule
target binding ligand, typically one for which a cocrystal structure
was available to define a suitable exit vector for the installation
of the linker. From the E3 binding side, the vast majority of PROTACs
are limited to just two ligases: CRBN, which is targeted by various
immunomodulatory drugs (IMiDs) such as thalidomide,<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> pomalidomide<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> or lenalidomide,<sup><xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref12">12</xref></sup> and VHL, for which high-affinity small molecule ligands were developed.<sup><xref ref-type="bibr" rid="ref13">13</xref>,<xref ref-type="bibr" rid="ref14">14</xref></sup></p>
    <p>A key challenge in PROTAC design to date is the selection
of the
optimal linker to connect these two binding components. In most cases,
linkers of various lengths are screened using synthetically accessible
chemistry.<sup><xref ref-type="bibr" rid="ref15">15</xref>−<xref ref-type="bibr" rid="ref19">19</xref></sup> In some cases, it was shown that arbitrarily long linkers can successfully
degrade their targets.<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> However, for other
systems, a protein–protein interface between the target and
the E3 ligase, including interactions with the linker, is important
for cooperativity.<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> Evidence is accumulating
that a stable ternary complex involving protein–protein interactions
is important for efficient degradation.<sup><xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref21">21</xref>,<xref ref-type="bibr" rid="ref22">22</xref></sup> Still, there is currently no way to predict or design
linkers which would allow, or promote, ternary complex formation,
a likely key parameter to a successful PROTAC. This gap necessitates
significant synthetic effort.</p>
    <p>Despite the increasing popularity
of PROTACs and the many examples
of experimentally validated, cell-active PROTACs, structural information
on Target/E3/PROTAC ternary complexes is still very limited. The ability
to model such ternary complexes can in theory inform the design of
more potent PROTACs, significantly reduce the number of linker designs
required to achieve efficient degradation, and rationalize the structure–activity
relationship of already known series of PROTACs. However, such modeling
efforts are still rare.</p>
    <p>A pioneering work in modeling PROTAC
mediated ternary complexes<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> explored four
methods to generate ensembles
of ternary complexes and had some success in recapitulating the very
few available crystal structures of such complexes. Recently, this
work was extended by the addition of clustering to improve its performance.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> Very recently, a new Rosetta-based protocol
was also reported that successfully rationalized PROTAC structure–activity
relationships.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> Some system specific modeling
efforts were also reported. For instance, docking followed by short
molecular dynamics simulations was used to model p38 isoforms in complex
with PROTACs and VHL and to predict residues that contribute to linker
interactions and selectivity of the PROTACs.<sup><xref ref-type="bibr" rid="ref5">5</xref>,<xref ref-type="bibr" rid="ref6">6</xref></sup> PROTAC
ensembles in the absence of the protein complex were used to define
distance distribution between the binding partners.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> HADDOCK<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> was used to dock Sirt2
and CRBN;<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> subsequent docking of a PROTAC
into the complex recapitulated the known binding modes of the separate
protein binding moieties. Notably, RosettaDock was used by Nowak et
al.<sup><xref ref-type="bibr" rid="ref29">29</xref></sup> to inform the design of selective
PROTACs. Molecular dynamics simulations were used to design a macrocyclic
PROTAC,<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> and two additional relevant computational
approaches for linker design were recently introduced<sup><xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref32">32</xref></sup> that can be used to design PROTAC linkers based on the protein–protein
binary complex. While these may be suitable as a subprocedure within
a general protocol, they cannot in and of themselves model ternary
complexes.</p>
    <p>Here, we present PRosettaC, a holistic protocol for
modeling PROTAC
mediated ternary complexes. It combines global docking with PatchDock<sup><xref ref-type="bibr" rid="ref33">33</xref>,<xref ref-type="bibr" rid="ref34">34</xref></sup> under PROTAC derived distance constraints and local docking with
RosettaDock,<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> followed by modeling of
the PROTAC into the ternary complex.<sup><xref ref-type="bibr" rid="ref36">36</xref></sup> The
protocol was able to accurately recover published structures of ternary
complexes to near atomic resolution and recapitulate experimental
trends for two model systems. This general protocol should be useful
in the design of new PROTACs for a wide variety of targets. To enable
wide access to this protocol, we have made available both the code
(<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/LondonLab/PRosettaC">https://github.com/LondonLab/PRosettaC</uri>) as well as a Web server for running PRosettaC (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://prosettac.weizmann.ac.il/">https://prosettac.weizmann.ac.il/</uri>).</p>
  </sec>
  <sec id="sec2">
    <title>Results</title>
    <sec id="sec2.1">
      <title>The PRosettaC Protocol</title>
      <p>The protocol includes several
consecutive steps, each intended to decrease the large conformational
search space which includes the protein–protein interaction
degrees of freedom, the PROTAC internal conformation and its pose
relative to the protein–protein complex (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>).</p>
      <fig id="fig1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>An overview of the PRosettaC protocol. The protocol
consists of
the following consecutive steps: 1. Sampling of the distance between
the two ligand anchor points. 2. Constrained global protein–protein
docking with PatchDock. 3. Local docking with RosettaDock. 4. Generating
constrained PROTAC conformations compatible with the local docking
solutions. 5. Clustering of the top scoring results.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00589_0001" id="gr1" position="float"/>
      </fig>
      <p>The input for the protocol is structures, or models, of the
protein
target and E3 ligase, each in complex with its own binding ligand,
as well as a SMILES string, representing the entire PROTAC (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>). Similar to Drummond
and Williams,<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> we use two anchor atoms
in the two ligands which are defined as part of the input. In most
cases, we arbitrarily chose the anchor atoms as the atoms through
which the PROTAC’s linker is attached to the two ligands, with
the exception of thalidomide, where the attachment atom is not uniquely
defined within the SMILES string, and thus we chose a more central
atom. Since the choice of anchor atoms is arbitrary, it should not
affect the results greatly, as long as the atom is uniquely defined
by SMILES.</p>
      <fig id="fig2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>The input for the PRosettaC protocol. A. The chemical structure
of a BRD4 PROTAC molecule including a CRBN ligand (thalidomide), a
BRD4 ligand (JQ1), and an alkane linker. B. Structure of CRBN with
thalidomide. C. Structure of BRD4 with JQ1. D. Thalidomide with the
anchor atom marked. E. JQ1 with the anchor atom marked. All structures
are based on PDB: 6BOY.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00589_0002" id="gr2" position="float"/>
      </fig>
      <sec id="sec2.1.1">
        <title>Step 1. Rough Sampling of the Distance between
the Anchor Points</title>
        <p>To estimate the distance between the anchor
atoms, we do the following:
for each value starting from 1 Å and in increments of 1 Å,
we generate 200 random pairs of ligand positions with the anchor distance
set to that value. Then, for each pair of ligand positions, we generate
a random conformation of the entire PROTAC which incorporates the
“fixed” ligand positions. Due to geometrical constraints
of the molecule, some of the pairs fail to generate a valid PROTAC
conformation while others succeed. We sum up the successfully generated
PROTAC conformations for each distance bin (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>A) and then pick distance constraints according
to the distribution of successful conformations (see the <xref rid="sec4" ref-type="other">Methods</xref>, Figure S1 and Table S1, for a detailed
explanation of the choice of distance constraints).</p>
        <fig id="fig3" position="float">
          <label>Figure 3</label>
          <caption>
            <p>Sampling the PROTAC anchor
points distance distribution successfully
constrains global docking. A. For each distance (in 1 Å increments),
we generate 200 random orientations of the target and E3 ligands and
try to generate PROTAC conformations to match these random orientations.
The histogram represents successfully generated conformations of an
example PROTAC (PDB: 6BOY). On the basis of this histogram, the constraints chosen for the
following step were 8—15 Å. Despite the crystallographic
distance falling outside the constraints boundaries in this example,
the protocol eventually is able to recapitulate the correct binding
mode. See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.0c00589/suppl_file/ci0c00589_si_001.pdf">Figure S1 and Table S1</ext-link> for more
details on boundary selection and the crystallographic distances.
B. Top 5 solutions of global protein–protein docking, constrained
by the range calculated by the previous step of the protocol. C. Top
5 solutions of unconstrained protein–protein docking. Green,
E3 ligase CRBN; dark blue, crystallographic BRD4 (6BOY); cyan, docked BRD4.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00589_0003" id="gr3" position="float"/>
        </fig>
      </sec>
      <sec id="sec2.1.2">
        <title>Step 2. Global Protein–Protein Docking</title>
        <p>We use
PatchDock, a very efficient global docking algorithm,<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> to sample the protein–protein interaction space.
The distance between the two anchors is forced to be within the constraints
calculated in the previous step. This limits the docking search space
considerably (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>B,C).</p>
      </sec>
      <sec id="sec2.1.3">
        <title>Step 3: Local Docking Refinement</title>
        <p>After using PatchDock
to rapidly sample the protein–protein interaction space, we
use RosettaDock<sup><xref ref-type="bibr" rid="ref37">37</xref></sup> local docking to produce
50 high-resolution models for each PatchDock global docking solution.
The anchor distance constraints are not incorporated in this step.
This allows the protocol to find a native solution, even if the crystallographic
anchor distance is slightly outside the range of the constraints,
like in the case of PDB: 6BOY (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>A).</p>
      </sec>
      <sec id="sec2.1.4">
        <title>Step 4: Modeling the PROTACs into the Docking Solutions</title>
        <p>We treat each of the local docking solutions as a hypothesis for
the final ternary complex (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>A). Thus, we constrain the ligands to be in the appropriate
positions, derived from the protein–protein docking (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>B), and construct
100 conformations of the full PROTAC that would fit these positions
(<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>C). In other
words, we create up to 100 random linker conformations which could
connect the two ligands, given their position in the docking solution.
For a significant portion of the local docking solutions, after 1,000
trials, no conformations could be found. Thus, no linker can attach
the two ligands in these conformations (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.0c00589/suppl_file/ci0c00589_si_001.pdf">Table S1</ext-link>). For example, for 6BOY, out of ∼36,000 local docking solutions, only
∼28,000 got at least one generated conformation (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.0c00589/suppl_file/ci0c00589_si_001.pdf">Table S1</ext-link>).</p>
        <fig id="fig4" position="float">
          <label>Figure 4</label>
          <caption>
            <p>Generating PROTAC conformations in the
context of the protein–protein
interaction. Using RDKit, we generate up to 100 PROTAC conformations,
to match the ligand orientation of each local docking solution. Then,
we use Rosetta Packer to choose the best conformation to fit the protein–protein
docking model. A. An example local docking solution for 6BOY. B. The ligand orientation,
extracted from the local docking solution. C. Constrained conformations
that bridge between the ligand orientation. D. Output model of Rosetta
after choosing the best constrained conformation. E. The conformation
chosen by Rosetta. Green, E3 ligase CRBN; cyan, predicted BRD4; light
pink, predicted PROTAC conformation.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00589_0004" id="gr4" position="float"/>
        </fig>
        <p>We use the Rosetta Packer<sup><xref ref-type="bibr" rid="ref38">38</xref></sup> to choose
the optimal linker conformation of those generated (if one exists)
that could connect the two ligands in the context of the docking solution
(<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>E). This step
outputs possible ternary complexes (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>D) and prevents clashes between the PROTAC
and the protein–protein complex. At this point, we filter complexes
with high a Rosetta energy score and exclude them from further analysis.</p>
      </sec>
      <sec id="sec2.1.5">
        <title>Step 5: Clustering Top Scoring Complexes</title>
        <p>After scoring
the ternary complexes from the last step, we cluster them, under the
assumption that near-native solutions will be sampled many times.
From the 1,000 models with the lowest Rosetta score, we choose the
200 with the best interface score (energy of the complex less the
energy of the separate components after side-chain minimization).
We cluster these 200 complexes with a threshold of 4 Å RMSD for
the moving chain using the DBSCAN<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> clustering
method and rank the clusters by the number of models in each cluster.
Between clusters of the same size, the ranking is based on the average
score of the final models. The 4 Å RMSD threshold was chosen
based on a manual inspection of similarity with different thresholds
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.0c00589/suppl_file/ci0c00589_si_001.pdf">Figure S2</ext-link>) and is consistent with accepted
criteria in protein–protein docking.<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> The “near-native” cluster is defined as the top cluster
which contains at least one near-native structure—a structure
with a target Cα RMSD below 4 Å to the crystallographic
conformation.</p>
      </sec>
    </sec>
    <sec id="sec2.2">
      <title>Optimization of Hyper Parameters</title>
      <p>The protocol contains
several parameters that require optimization. These include choosing
whether to use the entire E3 ligase complex from the crystal structure
or only the CRBN or VHL monomer; the RMSD threshold for clustering
the global docking results; the number of top scoring models to consider
for clustering; and the number of top interface scores within the
top scoring models. Choosing the optimal parameters was not straightforward
since there are only a handful of ternary structures available. We
chose to optimize them on a set of five structures which were previously
used for benchmarking<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> (PDB IDs: 6BOY, 6BN7, 6BN8, 6BN9,<sup><xref ref-type="bibr" rid="ref29">29</xref></sup>5T35<sup><xref ref-type="bibr" rid="ref4">4</xref></sup>). We tested a matrix of different combinations
for the five aforementioned parameters (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.0c00589/suppl_file/ci0c00589_si_001.pdf">Table S2</ext-link>). The choice of docking the E3 monomer or complex had little
effect, likely since the distance constraints to the global docking
already restrict the possible interaction interfaces, we hence chose
to use the monomer to reduce runtime. Increasing the number of RosettaDock
local docking models from 5 to 10 to 50 improved performance.</p>
    </sec>
    <sec id="sec2.3">
      <title>Accurate
Recapitulation of Ternary Complexes Using Bound Structures</title>
      <p>With the best combination of parameters, we were able to predict
near-native models for four out of the five cases in the train set.
In all four cases, the near-native models were found in the first
or second ranked clusters (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>; see <xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref> for the lowest RMSD solution and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.0c00589/suppl_file/ci0c00589_si_001.pdf">Figure S3</ext-link> for representatives of the top three clusters for each of
the four structures). Most of the native interactions were recapitulated
in these models (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.0c00589/suppl_file/ci0c00589_si_001.pdf">Table S3</ext-link> for a comparison
of the protein–protein interactions between the crystal and
model complexes, calculated using the PIC server<sup><xref ref-type="bibr" rid="ref41">41</xref></sup>).</p>
      <fig id="fig5" position="float">
        <label>Figure 5</label>
        <caption>
          <p>PRosettaC can recapitulate known ternary complexes to
atomic accuracy.
Upper panels: near native predictions for four structures of the training
set: 5T35, 6BOY, 6BN7 and 6BN9, with reported Cα
RMSD of the moving chain (BRD4), protein interface RMSD which is calculated
on all backbone atoms of residues which are within 8 Å of any
residue on the other protein, the RMSD over the small molecule ligands
(excluding the linker), and the RMSD over the entire PROTAC. Lower
panels: zoom in on the ligand binding predictions. In all four, PRosettaC
achieved predictions of atomic accuracy for the target ligands. Green,
E3 ligase CRBN; dark blue, X-ray BRD4; cyan, docked BRD4; magenta,
X-ray PROTAC conformation; light pink, predicted PROTAC conformation.
*Note that the PROTAC molecule is not resolved in 6BN9 and was modeled
by PRosettaC. The RMSD values for the ligands are based on alignment
to 6BN7. Since
the ligand–protein interactions are highly conserved, the ligand
RMSD, based on the alignment, should still be representative.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00589_0005" id="gr5" position="float"/>
      </fig>
      <table-wrap id="tbl1" position="float">
        <label>Table 1</label>
        <caption>
          <title>PRosettaC Performance against Known
Ternary Complex Structures</title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center"> </th>
              <th colspan="5" align="center">train<hr/></th>
              <th colspan="5" align="center">test<hr/></th>
            </tr>
            <tr>
              <th style="border:none;" align="center">PDB</th>
              <th style="border:none;" align="center">5T35</th>
              <th style="border:none;" align="center">6BOY</th>
              <th style="border:none;" align="center">6BN7</th>
              <th style="border:none;" align="center">6BN8</th>
              <th style="border:none;" align="center">6BN9</th>
              <th style="border:none;" align="center">6BNB</th>
              <th style="border:none;" align="center">6SIS</th>
              <th style="border:none;" align="center">6HAX</th>
              <th style="border:none;" align="center">6HAY</th>
              <th style="border:none;" align="center">6HR2</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:none;" align="left">rank<xref rid="t1fn1" ref-type="table-fn">a</xref></td>
              <td style="border:none;" align="left">2/46</td>
              <td style="border:none;" align="left">2/22</td>
              <td style="border:none;" align="left">1/29</td>
              <td style="border:none;" align="left">NA/51<xref rid="t1fn3" ref-type="table-fn">c</xref></td>
              <td style="border:none;" align="left">2/40</td>
              <td style="border:none;" align="left">1/20</td>
              <td style="border:none;" align="left">3/17</td>
              <td style="border:none;" align="left">71/76<xref rid="t1fn4" ref-type="table-fn">d</xref></td>
              <td style="border:none;" align="left">20/35<xref rid="t1fn4" ref-type="table-fn">d</xref></td>
              <td style="border:none;" align="left">18/61</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">RMSD &lt; 10 Å<xref rid="t1fn2" ref-type="table-fn">b</xref></td>
              <td style="border:none;" align="left">3.5%</td>
              <td style="border:none;" align="left">17.0%</td>
              <td style="border:none;" align="left">62.0%</td>
              <td style="border:none;" align="left">0.5%</td>
              <td style="border:none;" align="left">22.0%</td>
              <td style="border:none;" align="left">47.0%</td>
              <td style="border:none;" align="left">19.0%</td>
              <td style="border:none;" align="left">2.5%</td>
              <td style="border:none;" align="left">1.0%</td>
              <td style="border:none;" align="left">5%</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="t1fn1">
            <label>a</label>
            <p>Rank of the near-native cluster/total
number of clusters.</p>
          </fn>
          <fn id="t1fn2">
            <label>b</label>
            <p>Percent
of models that show less
than 10 Å RMSD to the crystal structure (performance measure
reported by Drummond and Williams<sup><xref ref-type="bibr" rid="ref23">23</xref></sup>).</p>
          </fn>
          <fn id="t1fn3">
            <label>c</label>
            <p>No near-native clusters were
found
for this structure.</p>
          </fn>
          <fn id="t1fn4">
            <label>d</label>
            <p>These
clusters were singletons,
i.e., contained a single structure.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec id="sec2.4">
      <title>Comparison of PRosettaC to Previously Reported Methods</title>
      <p>Drummond and Williams<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> reported the results
of their methods against five structures. To be able to compare our
results, we first had to realign the models, since they chose the
degradation target as the static chain, while we chose the E3 ligase,
due to the large size of CRBN compared to BRD4. The results (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.0c00589/suppl_file/ci0c00589_si_001.pdf">Table S4</ext-link>) are therefore based on the E3 Cα
RMSD. As a metric for success, they report the percent of models with
RMSD to the X-ray structure below 10 Å. In three cases (6BOY, 6BN7, and 6BN9), PRosettaC outperformed
their method. In one case (5T35), their method did better. Both methods performed
poorly on 6BN8. We should note that while Drummond and Williams were not able to
generate successful models for 6BOY, our method generated 17% such models,
ranking the native cluster in second place. Also, even though we could
not match the overall fraction of near native solutions for 5T35, we did rank the
cluster which includes the native structure in second place. To our
understanding, Drummond and Williams do not report ranking.</p>
    </sec>
    <sec id="sec2.5">
      <title>Application
to a New Set of Test Structures</title>
      <p>After optimizing
the hyper parameters on the training set (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.0c00589/suppl_file/ci0c00589_si_001.pdf">Table S2</ext-link>), we tested PRosettaC on five additional structures which
were not modeled in previous work (PDBs: 6BNB, 6SIS, 6HAX, 6HAY, 6HR2) nor optimized against. The most successful
out of these was 6BNB, a complex of BRD4 with CRBN (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>A), in which CRBN shows an “open” conformation,
substantially different from the closed conformation seen in most
structures. The top ranking cluster, which included 67.7% of the final
models, was the near-native cluster. The PROTAC molecule (dBET57)
is not modeled in the original structure, likely due to the low resolution
of the structure (6.3 Å). We placed the ligands by aligning structures
with the individual ligands onto 6BNB (using domains from 6BOY as templates). On
the basis of our prediction, we were able to easily model the PROTAC
(<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>A). A second
successful prediction was for a complex of VHL with BRD4 (PDB: 6SIS), bridged by a nonconventional
macrocyclic PROTAC.<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> The near native cluster
was ranked third, and the ligand binding moieties were recapitulated
with subangstrom accuracy (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>B). For the rest of the test cases, all complexes of
VHL with SMARCA2/4,<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> while near-native
clusters were found, they were not ranked highly (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>).</p>
      <fig id="fig6" position="float">
        <label>Figure 6</label>
        <caption>
          <p>Near native predictions
for two nontraditional PROTAC ternary complexes.
A. Near native prediction of PDB: 6BNB of a BRD4 PROTAC with an open conformation
of CRBN. The target Cα RMSD is 2.35 Å. The native cluster
was ranked 1, containing 67.7% of the final models. The PROTAC molecule
is not modeled in the original structure, but could be easily modeled
in using ProsettaC. B. Near native prediction of 6SIS, a complex of BRD4
and CRBN with a macrocyclic PROTAC. The target Cα RMSD is 1.3
Å, with a target ligand RMSD of 0.5 Å and a full PROTAC
RMSD of 0.72 Å. The native cluster was ranked 3. Green, E3 ligase;
dark blue, crystallographic BRD4; cyan, predicted BRD4; magenta, X-ray
PROTAC conformation; light pink, predicted PROTAC conformation.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00589_0006" id="gr6" position="float"/>
      </fig>
    </sec>
    <sec id="sec2.6">
      <title>PRosettaC Models Can Help to Explain Structure–Activity
Relationships</title>
      <p>The BRD4[BD2] triple mutant K378Q, E383V, and
A384K mimics the first bromodomain of BRD2. MZ1, the PROTAC from 5T35, selectively degrades
BRD4[BD2] over BRD2[BD1]. It was predicted and shown experimentally
that this triple mutant reduces ternary complex formation with VHL<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> and was previously used as a negative test case
for modeling.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> We introduced these three
mutations in silico (based on 5T35) and reran the protocol. While for the
wild-type BRD4, the native cluster was ranked second out of 46, containing
9% of the final models, none of 34 clusters proposed for the triple
mutant were near-native. This suggests that indeed these three positions
were crucial for the formation of the productive ternary complex.</p>
      <p>To test our method’s ability to predict unknown ternary complexes,
we next turned to a systematic study of PROTACs against BTK.<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> The authors tested 11 different PROTACs with
increasing linker lengths, between 5 and 21 atoms, for their ability
to degrade BTK, as well as for their ability to form a ternary complex
(using a TR-FRET experiment). PROTACs 1–4 cannot degrade BTK
efficiently nor lead to ternary complex formation at low concentrations.
PROTACs 6–11 were all efficient in both degrading BTK and forming
the ternary complex. The authors used computational modeling to recapitulate
their experimental results. Using a proprietary pipeline to create
models of the ternary complex they were able to produce nonclashing
models for PROTACs with longer linkers (PROTACs 7–11) but not
for PROTACs with shorter linkers (1–4).</p>
      <p>We applied PRosettaC
to this model system. We used a structure
of CRBN bound to lenalidomide (PDB: 4TZ4) after switching the lenalidomide to
thalidomide and a structure of mouse BTK (98% identical to human BTK)
bound to the inhibitor on which the PROTACs were based (PDB: 6MNY). Our results (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.0c00589/suppl_file/ci0c00589_si_001.pdf">Table S5</ext-link>) correlated very well with the experimental
data. The first distinction between the active and nonactive PROTACs
was the number of generated models. For PROTACs 1–3, our protocol
was not able to generate any ternary structure. For PROTACs 4 and
5, it generated less than 250 models and, for 6–11, more than
1,000 models. While the number of models itself was not indicative
of a successful prediction in our training and test sets, we noticed
that the top ranked clusters of PROTACs 5–11 were very similar,
but different for that of PROTAC 4. This suggests that the complex
represented by the top clusters of PROTACs 5–11 is a low energy
solution that may lead to efficient degradation. In order to find
a consensus structure within these top clusters, we pooled together
and clustered the top cluster from the separate runs of PROTACs 5–11
with a lower RMSD threshold of 1 Å. The top cluster was a tight
ensemble of 213 similar structures, still containing representatives
of PROTACs 5–11. To further fine-tune our prediction, we clustered
this top overall cluster with an even lower RMSD threshold of 0.5
Å. While the first subcluster did not contain representatives
of 5–11, the second one did, and included 33 structures, forming
a very tight ensemble (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig">7</xref></xref>A).</p>
      <fig id="fig7" position="float">
        <label>Figure 7</label>
        <caption>
          <p>High confidence prediction of a BTK–CRBN ternary complex.
Modeling of a BTK–CRBN ternary complex, with a series of 11
PROTACs, recapitulates which PROTACs are active and which are not
and suggests a high-confidence model for the interaction. A. A cluster
(with 0.5 Å threshold) of 33 models from various PRosettaC runs
contains representatives from active PROTACs 5–11. B. Representative
of PROTACs 5–11: 5, brown; 6, gray; 7, magenta; 8, yellow;
9, orange; 10, purple; 11, green.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00589_0007" id="gr7" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec id="sec3">
    <title>Discussion</title>
    <p>The field of PROTAC mediated targeted degradation
is gaining tremendous
momentum, as highlighted by the recent positive results from the first
PROTAC (ARV-110) to enter clinical trials.<sup><xref ref-type="bibr" rid="ref43">43</xref></sup> Structure-based design is a key paradigm in drug discovery, and
PROTAC design can clearly benefit from structural insights, as evidenced
by the few cases in which ternary complex structures were actually
determined. Gadd et al.<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> used the structure
of the BRD4/VHL/MZ1 ternary complex to design a new PROTAC (AT1) in
which the linker uses a different exit vector from the VHL ligand.<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> Testa et al.<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> used
the same structure in order to create a macrocyclic PROTAC with improved
selectivity. Farnaby et al.<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> used the
complex of the SMARCA2/VHL/PROTAC-1 complex to rigidify the PROTAC
linker and introduce a new π-stacking interaction, resulting
in a significantly improved molecule. In the absence of ternary complex
experimental structures, PROTAC designers can turn to modeling in
order to generate design hypotheses.</p>
    <p>Modeling of PROTAC mediated
ternary complexes, however, is a challenging
task for multiple reasons. First is the very small number of available
structures of such interactions, which complicates the benchmarking
of new methods. Second, is the fact that the E3 ligase and protein
target are not cognate interaction partners, thus any binding interface
that may be stabilized by the PROTAC is likely transient with weak
affinity.<sup><xref ref-type="bibr" rid="ref44">44</xref>−<xref ref-type="bibr" rid="ref46">46</xref></sup> Such low affinity PPIs are known to be challenging
for docking methods.<sup><xref ref-type="bibr" rid="ref47">47</xref></sup> Another difficulty
is the need to simultaneously model protein–protein interactions
and protein–ligand interactions, the latter often with a significant
number of rotatable bonds.</p>
    <p>Here, we presented a general approach
which overcomes some of the
challenges by using the PROTAC’s distance distribution to restrict
the protein–protein docking search space and then uses the
docking solution to restrict the ligand conformational search space.
PRosettaC was very successful in recapitulating the ternary complexes
in 6 out of 10 cases. Moreover, the near-native models were ranked
in the top three solutions. It was further able to recapitulate trends
for a series of BTK targeting PROTACs and propose a high-confidence
model for the BTK/CRBN ternary complex, by combining the experimental
results from various PROTACs.<sup><xref ref-type="bibr" rid="ref20">20</xref></sup></p>
    <p>On
the basis of these successful results, we suspect that PRosettaC
would be a useful tool to enable structure-based PROTAC design. The
fact that in most cases the near-native complex was ranked in the
top three clusters suggests that in the future a small number of PROTACs
that are designed based on a limited number of the top clusters could
be used to validate which model captures the productive complex that
leads to degradation.</p>
    <p>One design prediction already emerged
based on the modeling of
the BRD4/CRBN/dBET23 complex (PDB: 6BN7), for which PRosettaC identified the
native cluster as the top ranking solution, including 65.5% of the
final structures. In this case, the protein–protein interaction
was accurately recapitulated, as were the thalidomide and BRD4 ligand
moieties. However, a flip of the thalidomide phthalimide, which scored
better, forced the linker to exit out of the opposite atom compared
to the one observed in the crystal structure (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>). Testa et al. previously used the structure
of BRD4/VHL/MZ1 elegantly to create a macrocyclic PROTAC.<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> The 6BN7 modeling result suggests a similar strategy would
work for the BRD4/CRBN complex as well (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.0c00589/suppl_file/ci0c00589_si_001.pdf">Figure S4</ext-link>).</p>
    <p>Despite its success, our protocol still suffers
from some challenges.
In the set of the original five test structures, PRosettaC was least
successful for 6BN8, a complex of BRD4/CRBN and the PROTAC dBET55 for which the native
solution did not belong to any of the clusters. dBET55 contains a
very long PEG9 linker. The length and flexibility of the linker presents
a problem for the anchor distance sampling step, and later to global
docking, which runs with very loose constraints. Indeed, global docking
produced an exceptionally large number of structures, and most near-native
solutions were not ranked among the top 1,000 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.0c00589/suppl_file/ci0c00589_si_001.pdf">Figure S5</ext-link>). Since such long and flexible linkers are rare
for PROTACs, we do not consider this a significant failure. For another
three cases involving complexes of VHL with SMARCA2/4, PRosettaC was
able to sample near-native solutions but did not rank them as one
of the top clusters. Analysis of the global docking results (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.0c00589/suppl_file/ci0c00589_si_001.pdf">Figure S5</ext-link>) suggests that not sampling a near-native
conformation for these complexes in the global docking step may be
the reason for these failures. Future developments may investigate
optimization or alternatives to the global docking step. One possibility
is that the crystal structure represents a single possible conformation
for the interaction, stabilized by crystal contacts (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.0c00589/suppl_file/ci0c00589_si_001.pdf">Figure S6</ext-link>), while other conformations proposed by our protocol
may be sampled in the solution state. Indeed, Nowak et al. used such
a “non-native” docking prediction to guide the design
of a new and more selective PROTAC,<sup><xref ref-type="bibr" rid="ref29">29</xref></sup> strongly
suggesting that such additional conformations are sampled in solution
and can be accessed by a suitable PROTAC. Hence, even if the top predicted
clusters do not correspond to the crystal structure, they may still
represent attractive opportunities for PROTAC design.</p>
    <p>Another
important caveat of this (and previous<sup><xref ref-type="bibr" rid="ref23">23</xref></sup>) benchmark is the use of the bound structures. Ideally,
the protocol should be able to reproduce the ternary complex starting
from the structures of the unbound monomers. Currently, PRosettaC
fails to rank near-native clusters when starting from unbound structures.
Future improvements to the protocol may address some of the aforementioned
challenges. Introduction of backbone flexibility may significantly
improve complex prediction based on unbound structures as was reported
for various docking approaches.<sup><xref ref-type="bibr" rid="ref48">48</xref>−<xref ref-type="bibr" rid="ref56">56</xref></sup> Incorporation of additional biological constraints such as the location
of the target lysine for ubiquitination, or known mutations that enhance/decrease
complex formation, may further restrict the conformational space.</p>
    <p>Despite these caveats, we present an end-to-end approach to model
target/E3-ligase/PROTAC ternary complexes. Our method leverages the
advantages of the highly constrained search space of this unique problem.
We demonstrated how the use of various experimental results can lead
to high confidence in our prediction. While still lacking prospective
experimental proof, this work may contribute to future in-silico design
of new PROTACs and may significantly reduce the time and resources
that are currently required for the design of PROTACs against a new
target.</p>
  </sec>
  <sec id="sec4">
    <title>Methods</title>
    <sec id="sec4.1">
      <title>Preparation of Input Files</title>
      <p>The PDB
files were downloaded
from the PDB (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.rcsb.org/">https://www.rcsb.org/</uri>). The chains of the E3 ligase and the target protein were cleaned
from any nonprotein atoms. The ligands were extracted manually from
the PROTAC in the PDB. In cases where the PROTAC was not modeled into
the structure (6BN8, 6BN9, 6BNB), we aligned another
structure(s) with the same domains and ligands and copied the ligand
coordinates. We added hydrogens to the ligands using OpenBabel (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://openbabel.org/wiki/Main_Page">http://openbabel.org/wiki/Main_Page</uri>). We added the protonated ligands to the structures, which then
underwent side-chain repacking and minimization.<sup><xref ref-type="bibr" rid="ref36">36</xref></sup> Next, in order to keep the original coordinates and atom
numbers, we replaced the ligand with their preminimized version. The
linker SMILES representation was taken from the PDB. In cases where
it was not modeled in the PDB, it was taken from the paper where they
were reported. Input files for the bound examples (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>) are available at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://zenodo.org/record/3967246#.XyLML_gzZQJ">https://zenodo.org/record/3967246#.XyLML_gzZQJ</uri>.</p>
    </sec>
    <sec id="sec4.2">
      <title>Estimating Linker Distance Constraints</title>
      <p>We sample the
length of the PROTAC in the following fashion. For each bin starting
with 1 Å, with increments of 1 Å, we made 200 random trials
to produce a PROTAC conformation. In each trial, a random orientation
of the two ligands is produced, while keeping the anchors in the distance
set by the bin “b.” This is done by generating a random
conformation of the two ligands and transforming them such that the
anchors are at (0,0,0), (b,0,0), followed by a random rotation of
both of them around the anchors. Then, using RDKit, we attempt to
create a valid PROTAC conformation based on the randomized ligand
orientation. Once an orientation is generated, we remeasure the distance
between the two anchors, to make sure it stays closer than 0.5 Å
from the distance set by the bin. We stopped this procedure when at
least 10 bins had been sampled, and we reached a bin for which no
conformations were generated. We sum up the number of successful conformations
generated in each bin, to generate a histogram. From the histogram,
we take the highest value, multiply it by 0.75, and set it as a threshold.
Then, we take the minimum and maximum bin values that achieve that
threshold: minA and maxA. Due to some cases where only a few bins
were populated, we also take the average bin value of all generated
conformations plus and minus 2 Å as minB and maxB. The final
distance constraints for the two anchors are min(minA, minB) and max(maxA,
maxB).</p>
    </sec>
    <sec id="sec4.3">
      <title>Constrained Global Protein–Protein Docking</title>
      <p>Global
docking is performed with PatchDock,<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> using
the downloadable linux version of the program. The constraints from
the previous step are incorporated in the parameters file. The output
includes solutions of the protein–protein docking problem,
clustered by a cutoff of 2 Å. Up to 1,000 global docking solutions
are considered for the next step.</p>
    </sec>
    <sec id="sec4.4">
      <title>Local Docking of Selected
Global Docking Solutions</title>
      <p>RosettaDock<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> local docking is used to
create up to 50 local docking results for each global docking solution
produced by PatchDock, treating the ligands as extra residues with
a fixed conformation.</p>
    </sec>
    <sec id="sec4.5">
      <title>Constrained PROTAC Conformation Generation
in the Context of
the Docking Solution</title>
      <p>We use RDKit to produce up to 100 conformations
of the PROTAC, with the constraints of the two ligands to fit the
local docking solution. Therefore, only the linker’s conformation
is being sampled, in regard to a fixed conformation and position of
the two ligands. Due to the constraints being atom-distance-based,
the conformation that is generated is not aligned with the position
of the ligands, and another alignment step is necessary. After the
alignment, a threshold of 0.5 Å RMSD between each ligand independently
and its X-ray conformation is used to ensure that the conformation
of the ligands is really the same as their native conformation. This
is necessary because RDKit generation of constrained conformations,
which is based on atom distances, can result in conformations not
fully within the desired constraints. If after 1,000 trials no valid
conformation has been generated, the local docking pose is discarded.
For the unbound and BTK-CRBN runs, this number was reduced to 100
for efficiency. For 6SIS, 6HAX, 6HAY, and 6HR2, an extra atom was
added to the E3 binding ligand, in order to uniquely define the position
of the exit vector, making sure the constrained conformation attaches
the linker to the right atom.</p>
    </sec>
    <sec id="sec4.6">
      <title>Modeling the PROTAC within
the Ternary Complex</title>
      <p>We use
Rosetta’s repack<sup><xref ref-type="bibr" rid="ref36">36</xref></sup> protocol to choose
the best PROTAC conformation from the set generated in the previous
step. In the repack protocol, the side-chains of the residues are
allowed to switch rotamers. We supplied the constrained conformations
which we generated using RDKit as rotamers for the PROTAC, using the
first one as the initial rotamer. Since the Rosetta Packer aligns
conformations based on a single atom (called the neighboring atom),
we added three virtual atoms with fixed coordinates to the set of
generated residue conformations. The center virtual atom has the coordinates
of the center of mass of the two ligands, while the two other virtual
atoms are 1 Å away from it, on the <italic>x</italic> and <italic>y</italic> axes. The two other atoms are connected to the center
virtual atom, which is defined as the neighboring atom, thus defining
a fixed 3D alignment, which does not translate the sampled conformations
and avoids lever-arm effects. Repacking was applied on the PROTAC,
as well as any residue that is within 10 Å distance from it.
After repacking, a final step of side-chain minimization for the entire
structure, excluding the PROTAC, was applied. Models with a final
score ≥0 are excluded from further analysis.</p>
    </sec>
    <sec id="sec4.7">
      <title>Clustering
Top Scoring Complexes</title>
      <p>We used the DBSCAN<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> clustering method and ranked the clusters by
the number of models in each cluster, assuming the highly populated
clusters would represent the best solutions. The DBSCAN method can
work either with coordinates of points in <italic>n</italic> dimensions
or with a distance matrix of precomputed distances between each pair
of points. Since we used Cα RMSD values of the moving chain
(defined always as the target protein), we precalculated all the pairwise
RMSDs between the final solutions and fed it to DBSCAN as the distance
matrix. We used 4 Å RMSD as the clustering threshold. We clustered
the top 200 solutions based on the interface score reported by Rosetta
(energy of the complex less the energy of the separate components
after side-chain minimization), out of the top 1,000 scoring final
solutions, created by Rosetta’s repacking protocol. We ranked
the clusters according to the number of structures in each cluster.
Between clusters of the same size, the ranking was based on the average
score of the final models. We define a native cluster as having at
least one member whose Cα RMSD from the native conformation
is lower than 4 Å. The reported rank is the top ranked cluster
among the native clusters.</p>
      <sec id="sec4.7.1">
        <title>Software and Files</title>
        <p><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://zenodo.org/record/3967246#.XyLML_gzZQJ">https://zenodo.org/record/3967246#.XyLML_gzZQJ</uri> includes the input files for the bound results, the final clusters
of the train and test sets (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>), the unsuccessful unbound results for the train set,
the CRBN-BTK final models, and the best RMSD models after renumbering
the residues, for which a detailed analysis of the protein–protein
interaction was performed (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.0c00589/suppl_file/ci0c00589_si_001.pdf">Table S3</ext-link>). The
Rosetta version used in this study is 2019.27.post.dev+132.master.966c9eb966c9eb6b3ab993de7aa3af5988125b7c2e464af
git@github.com: RosettaCommons/main.git 2019–07–18T11:43:25.
Rosetta was applied using RosettaScripts.<sup><xref ref-type="bibr" rid="ref57">57</xref></sup> The Python version used in the study is 2.7.14. However, for the
Web server and git repository, it was implemented in Python version
3.7.6. The RDKit version used in the study is 2018–09–03.
However, for the Web server, the version was updated to 2020–03–03.
The PatchDock executable was downloaded from <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://bioinfo3d.cs.tau.ac.il/PatchDock">https://bioinfo3d.cs.tau.ac.il/PatchDock</uri>.</p>
      </sec>
    </sec>
  </sec>
</body>
<back>
  <notes id="NOTES-d7e968-autogenerated" notes-type="si">
    <title>Supporting Information Available</title>
    <p>The Supporting Information is available
free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.jcim.0c00589?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.0c00589</ext-link>.<list id="silist" list-type="simple"><list-item><p>Supplementary figures
and tables (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jcim.0c00589/suppl_file/ci0c00589_si_001.pdf">PDF</ext-link>)</p></list-item></list></p>
  </notes>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sifile1">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci0c00589_si_001.pdf">
        <caption>
          <p>ci0c00589_si_001.pdf</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <notes notes-type="COI-statement" id="NOTES-d7e981-autogenerated">
    <p>The authors
declare no
competing financial interest.</p>
  </notes>
  <ack>
    <title>Acknowledgments</title>
    <p>We would like
to thank the Rosetta Commons, and
in particular Drs. Rocco Moretti and Steven Lewis, for much help with
algorithmic details. N.L. is the incumbent of the Alan and Laraine
Fischer Career Development Chair. N.L. would like to acknowledge funding
from the Israel Science Foundation (grant no. 2462/19), The Israel
Cancer Research Fund, the Israeli Ministry of Science and Technology
(grant no. 3-14763), the Moross Integrated Cancer Center, and the
Dr. Barry Sherman institute for Medicinal Chemistry. N.L. is also
supported by the Estate of Emile Mimran, Rising Tide Foundation, Honey
and Dr. Barry Sherman Lab, and Nelson P. Sirotsky. D.Z. would like
to acknowledge the Pearlman Grant for student-initiated research in
chemistry from the Faculty of Chemistry, the Weizmann Institute.</p>
  </ack>
  <ref-list>
    <title>References</title>
    <ref id="ref1">
      <mixed-citation publication-type="journal" id="cit1"><name><surname>Toure</surname><given-names>M.</given-names></name>; <name><surname>Crews</surname><given-names>C. M.</given-names></name><article-title>Small-Molecule PROTACS:
New Approaches to Protein Degradation</article-title>. <source>Angew.
Chem., Int. Ed.</source><year>2016</year>, <volume>55</volume>, <fpage>1966</fpage>–<lpage>1973</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201507978</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref2">
      <mixed-citation publication-type="journal" id="cit2"><name><surname>Neklesa</surname><given-names>T. K.</given-names></name>; <name><surname>Winkler</surname><given-names>J. D.</given-names></name>; <name><surname>Crews</surname><given-names>C. M.</given-names></name><article-title>Targeted Protein Degradation by PROTACs</article-title>. <source>Pharmacol. Ther.</source><year>2017</year>, <volume>174</volume>, <fpage>138</fpage>–<lpage>144</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2017.02.027</pub-id>.<pub-id pub-id-type="pmid">28223226</pub-id></mixed-citation>
    </ref>
    <ref id="ref3">
      <mixed-citation publication-type="journal" id="cit3"><name><surname>Pettersson</surname><given-names>M.</given-names></name>; <name><surname>Crews</surname><given-names>C. M.</given-names></name><article-title>Proteolysis TArgeting
Chimeras (PROTACs)—past,
Present and Future</article-title>. <source>Drug Discovery Today: Technol.</source><year>2019</year>, <volume>31</volume>, <fpage>15</fpage><pub-id pub-id-type="doi">10.1016/j.ddtec.2019.01.002</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref4">
      <mixed-citation publication-type="journal" id="cit4"><name><surname>Gadd</surname><given-names>M. S.</given-names></name>; <name><surname>Testa</surname><given-names>A.</given-names></name>; <name><surname>Lucas</surname><given-names>X.</given-names></name>; <name><surname>Chan</surname><given-names>K.-H.</given-names></name>; <name><surname>Chen</surname><given-names>W.</given-names></name>; <name><surname>Lamont</surname><given-names>D. J.</given-names></name>; <name><surname>Zengerle</surname><given-names>M.</given-names></name>; <name><surname>Ciulli</surname><given-names>A.</given-names></name><article-title>Structural Basis of
PROTAC Cooperative Recognition for Selective Protein Degradation</article-title>. <source>Nat. Chem. Biol.</source><year>2017</year>, <volume>13</volume>, <fpage>514</fpage>–<lpage>521</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.2329</pub-id>.<pub-id pub-id-type="pmid">28288108</pub-id></mixed-citation>
    </ref>
    <ref id="ref5">
      <mixed-citation publication-type="journal" id="cit5"><name><surname>Smith</surname><given-names>B. E.</given-names></name>; <name><surname>Wang</surname><given-names>S. L.</given-names></name>; <name><surname>Jaime-Figueroa</surname><given-names>S.</given-names></name>; <name><surname>Harbin</surname><given-names>A.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Hamman</surname><given-names>B. D.</given-names></name>; <name><surname>Crews</surname><given-names>C. M.</given-names></name><article-title>Differential PROTAC Substrate Specificity
Dictated by Orientation of Recruited E3 Ligase</article-title>. <source>Nat. Commun.</source><year>2019</year>, <volume>10</volume>, <fpage>131</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-08027-7</pub-id>.<pub-id pub-id-type="pmid">30631068</pub-id></mixed-citation>
    </ref>
    <ref id="ref6">
      <mixed-citation publication-type="journal" id="cit6"><name><surname>Bondeson</surname><given-names>D. P.</given-names></name>; <name><surname>Smith</surname><given-names>B. E.</given-names></name>; <name><surname>Burslem</surname><given-names>G. M.</given-names></name>; <name><surname>Buhimschi</surname><given-names>A. D.</given-names></name>; <name><surname>Hines</surname><given-names>J.</given-names></name>; <name><surname>Jaime-Figueroa</surname><given-names>S.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Hamman</surname><given-names>B. D.</given-names></name>; <name><surname>Ishchenko</surname><given-names>A.</given-names></name>; <name><surname>Crews</surname><given-names>C. M.</given-names></name><article-title>Lessons in PROTAC Design from Selective
Degradation with a Promiscuous Warhead</article-title>. <source>Cell
Chem. Biol.</source><year>2018</year>, <volume>25</volume>, <fpage>78</fpage>–<lpage>87</lpage>. <comment>e5</comment><pub-id pub-id-type="doi">10.1016/j.chembiol.2017.09.010</pub-id>.<pub-id pub-id-type="pmid">29129718</pub-id></mixed-citation>
    </ref>
    <ref id="ref7">
      <mixed-citation publication-type="journal" id="cit7"><name><surname>Huang</surname><given-names>H.-T.</given-names></name>; <name><surname>Dobrovolsky</surname><given-names>D.</given-names></name>; <name><surname>Paulk</surname><given-names>J.</given-names></name>; <name><surname>Yang</surname><given-names>G.</given-names></name>; <name><surname>Weisberg</surname><given-names>E. L.</given-names></name>; <name><surname>Doctor</surname><given-names>Z. M.</given-names></name>; <name><surname>Buckley</surname><given-names>D. L.</given-names></name>; <name><surname>Cho</surname><given-names>J.-H.</given-names></name>; <name><surname>Ko</surname><given-names>E.</given-names></name>; <name><surname>Jang</surname><given-names>J.</given-names></name>; <name><surname>Shi</surname><given-names>K.</given-names></name>; <name><surname>Choi</surname><given-names>H. G.</given-names></name>; <name><surname>Griffin</surname><given-names>J. D.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Treon</surname><given-names>S. P.</given-names></name>; <name><surname>Fischer</surname><given-names>E. S.</given-names></name>; <name><surname>Bradner</surname><given-names>J. E.</given-names></name>; <name><surname>Tan</surname><given-names>L.</given-names></name>; <name><surname>Gray</surname><given-names>N. S.</given-names></name><article-title>A Chemoproteomic
Approach to Query the Degradable Kinome
Using a Multi-Kinase Degrader</article-title>. <source>Cell Chem. Biol.</source><year>2018</year>, <volume>25</volume>, <fpage>88</fpage>–<lpage>99</lpage>. <comment>e6</comment><pub-id pub-id-type="doi">10.1016/j.chembiol.2017.10.005</pub-id>.<pub-id pub-id-type="pmid">29129717</pub-id></mixed-citation>
    </ref>
    <ref id="ref8">
      <mixed-citation publication-type="journal" id="cit8"><name><surname>Bondeson</surname><given-names>D. P.</given-names></name>; <name><surname>Mares</surname><given-names>A.</given-names></name>; <name><surname>Smith</surname><given-names>I. E. D.</given-names></name>; <name><surname>Ko</surname><given-names>E.</given-names></name>; <name><surname>Campos</surname><given-names>S.</given-names></name>; <name><surname>Miah</surname><given-names>A. H.</given-names></name>; <name><surname>Mulholland</surname><given-names>K. E.</given-names></name>; <name><surname>Routly</surname><given-names>N.</given-names></name>; <name><surname>Buckley</surname><given-names>D. L.</given-names></name>; <name><surname>Gustafson</surname><given-names>J. L.</given-names></name>; <name><surname>Zinn</surname><given-names>N.</given-names></name>; <name><surname>Grandi</surname><given-names>P.</given-names></name>; <name><surname>Shimamura</surname><given-names>S.</given-names></name>; <name><surname>Bergamini</surname><given-names>G.</given-names></name>; <name><surname>Faelth-Savitski</surname><given-names>M.</given-names></name>; <name><surname>Bantscheff</surname><given-names>M.</given-names></name>; <name><surname>Cox</surname><given-names>C.</given-names></name>; <name><surname>Gordon</surname><given-names>D. A.</given-names></name>; <name><surname>Willard</surname><given-names>R. R.</given-names></name>; <name><surname>Flanagan</surname><given-names>J. J.</given-names></name>; <name><surname>Casillas</surname><given-names>L. N.</given-names></name>; <name><surname>Votta</surname><given-names>B. J.</given-names></name>; <name><surname>den Besten</surname><given-names>W.</given-names></name>; <name><surname>Famm</surname><given-names>K.</given-names></name>; <name><surname>Kruidenier</surname><given-names>L.</given-names></name>; <name><surname>Carter</surname><given-names>P. S.</given-names></name>; <name><surname>Harling</surname><given-names>J. D.</given-names></name>; <name><surname>Churcher</surname><given-names>I.</given-names></name>; <name><surname>Crews</surname><given-names>C. M.</given-names></name><article-title>Catalytic
in Vivo Protein Knockdown by Small-Molecule PROTACs</article-title>. <source>Nat. Chem. Biol.</source><year>2015</year>, <volume>11</volume>, <fpage>611</fpage>–<lpage>617</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.1858</pub-id>.<pub-id pub-id-type="pmid">26075522</pub-id></mixed-citation>
    </ref>
    <ref id="ref9">
      <mixed-citation publication-type="journal" id="cit9"><name><surname>Fischer</surname><given-names>E. S.</given-names></name>; <name><surname>Böhm</surname><given-names>K.</given-names></name>; <name><surname>Lydeard</surname><given-names>J. R.</given-names></name>; <name><surname>Yang</surname><given-names>H.</given-names></name>; <name><surname>Stadler</surname><given-names>M. B.</given-names></name>; <name><surname>Cavadini</surname><given-names>S.</given-names></name>; <name><surname>Nagel</surname><given-names>J.</given-names></name>; <name><surname>Serluca</surname><given-names>F.</given-names></name>; <name><surname>Acker</surname><given-names>V.</given-names></name>; <name><surname>Lingaraju</surname><given-names>G. M.</given-names></name>; <name><surname>Tichkule</surname><given-names>R. B.</given-names></name>; <name><surname>Schebesta</surname><given-names>M.</given-names></name>; <name><surname>Forrester</surname><given-names>W. C.</given-names></name>; <name><surname>Schirle</surname><given-names>M.</given-names></name>; <name><surname>Hassiepen</surname><given-names>U.</given-names></name>; <name><surname>Ottl</surname><given-names>J.</given-names></name>; <name><surname>Hild</surname><given-names>M.</given-names></name>; <name><surname>Beckwith</surname><given-names>R. E. J.</given-names></name>; <name><surname>Harper</surname><given-names>J. W.</given-names></name>; <name><surname>Jenkins</surname><given-names>J. L.</given-names></name>; <name><surname>Thomä</surname><given-names>N. H.</given-names></name><article-title>Structure of the DDB1–CRBN
E3 Ubiquitin Ligase in Complex with Thalidomide</article-title>. <source>Nature</source><year>2014</year>, <volume>512</volume>, <fpage>49</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1038/nature13527</pub-id>.<pub-id pub-id-type="pmid">25043012</pub-id></mixed-citation>
    </ref>
    <ref id="ref10">
      <mixed-citation publication-type="journal" id="cit10"><name><surname>Lu</surname><given-names>J.</given-names></name>; <name><surname>Qian</surname><given-names>Y.</given-names></name>; <name><surname>Altieri</surname><given-names>M.</given-names></name>; <name><surname>Dong</surname><given-names>H.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Raina</surname><given-names>K.</given-names></name>; <name><surname>Hines</surname><given-names>J.</given-names></name>; <name><surname>Winkler</surname><given-names>J. D.</given-names></name>; <name><surname>Crew</surname><given-names>A. P.</given-names></name>; <name><surname>Coleman</surname><given-names>K.</given-names></name>; <name><surname>Crews</surname><given-names>C. M.</given-names></name><article-title>Hijacking the E3 Ubiquitin Ligase
Cereblon to Efficiently Target BRD4</article-title>. <source>Chem. Biol.</source><year>2015</year>, <volume>22</volume>, <fpage>755</fpage>–<lpage>763</lpage>. <pub-id pub-id-type="doi">10.1016/j.chembiol.2015.05.009</pub-id>.<pub-id pub-id-type="pmid">26051217</pub-id></mixed-citation>
    </ref>
    <ref id="ref11">
      <mixed-citation publication-type="journal" id="cit11"><name><surname>Qin</surname><given-names>C.</given-names></name>; <name><surname>Hu</surname><given-names>Y.</given-names></name>; <name><surname>Zhou</surname><given-names>B.</given-names></name>; <name><surname>Fernandez-Salas</surname><given-names>E.</given-names></name>; <name><surname>Yang</surname><given-names>C.-Y.</given-names></name>; <name><surname>Liu</surname><given-names>L.</given-names></name>; <name><surname>McEachern</surname><given-names>D.</given-names></name>; <name><surname>Przybranowski</surname><given-names>S.</given-names></name>; <name><surname>Wang</surname><given-names>M.</given-names></name>; <name><surname>Stuckey</surname><given-names>J.</given-names></name>; <name><surname>Meagher</surname><given-names>J.</given-names></name>; <name><surname>Bai</surname><given-names>L.</given-names></name>; <name><surname>Chen</surname><given-names>Z.</given-names></name>; <name><surname>Lin</surname><given-names>M.</given-names></name>; <name><surname>Yang</surname><given-names>J.</given-names></name>; <name><surname>Ziazadeh</surname><given-names>D. N.</given-names></name>; <name><surname>Xu</surname><given-names>F.</given-names></name>; <name><surname>Hu</surname><given-names>J.</given-names></name>; <name><surname>Xiang</surname><given-names>W.</given-names></name>; <name><surname>Huang</surname><given-names>L.</given-names></name>; <name><surname>Li</surname><given-names>S.</given-names></name>; <name><surname>Wen</surname><given-names>B.</given-names></name>; <name><surname>Sun</surname><given-names>D.</given-names></name>; <name><surname>Wang</surname><given-names>S.</given-names></name><article-title>Discovery of QCA570 as an Exceptionally
Potent and
Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the
Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing
Complete and Durable Tumor Regression</article-title>. <source>J. Med.
Chem.</source><year>2018</year>, <volume>61</volume>, <fpage>6685</fpage>–<lpage>6704</lpage>. <comment>Others.</comment><pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b00506</pub-id>.<pub-id pub-id-type="pmid">30019901</pub-id></mixed-citation>
    </ref>
    <ref id="ref12">
      <mixed-citation publication-type="journal" id="cit12"><name><surname>Chamberlain</surname><given-names>P. P.</given-names></name>; <name><surname>Lopez-Girona</surname><given-names>A.</given-names></name>; <name><surname>Miller</surname><given-names>K.</given-names></name>; <name><surname>Carmel</surname><given-names>G.</given-names></name>; <name><surname>Pagarigan</surname><given-names>B.</given-names></name>; <name><surname>Chie-Leon</surname><given-names>B.</given-names></name>; <name><surname>Rychak</surname><given-names>E.</given-names></name>; <name><surname>Corral</surname><given-names>L. G.</given-names></name>; <name><surname>Ren</surname><given-names>Y. J.</given-names></name>; <name><surname>Wang</surname><given-names>M.</given-names></name>; <name><surname>Riley</surname><given-names>M.</given-names></name>; <name><surname>Delker</surname><given-names>S. L.</given-names></name>; <name><surname>Ito</surname><given-names>T.</given-names></name>; <name><surname>Ando</surname><given-names>H.</given-names></name>; <name><surname>Mori</surname><given-names>T.</given-names></name>; <name><surname>Hirano</surname><given-names>Y.</given-names></name>; <name><surname>Handa</surname><given-names>H.</given-names></name>; <name><surname>Hakoshima</surname><given-names>T.</given-names></name>; <name><surname>Daniel</surname><given-names>T. O.</given-names></name>; <name><surname>Cathers</surname><given-names>B. E.</given-names></name><article-title>Structure of the
Human Cereblon–DDB1–lenalidomide Complex Reveals Basis
for Responsiveness to Thalidomide Analogs</article-title>. <source>Nat.
Struct. Mol. Biol.</source><year>2014</year>, <volume>21</volume>, <fpage>803</fpage>–<lpage>809</lpage>. <pub-id pub-id-type="doi">10.1038/nsmb.2874</pub-id>.<pub-id pub-id-type="pmid">25108355</pub-id></mixed-citation>
    </ref>
    <ref id="ref13">
      <mixed-citation publication-type="journal" id="cit13"><name><surname>Van
Molle</surname><given-names>I.</given-names></name>; <name><surname>Thomann</surname><given-names>A.</given-names></name>; <name><surname>Buckley</surname><given-names>D. L.</given-names></name>; <name><surname>So</surname><given-names>E. C.</given-names></name>; <name><surname>Lang</surname><given-names>S.</given-names></name>; <name><surname>Crews</surname><given-names>C. M.</given-names></name>; <name><surname>Ciulli</surname><given-names>A.</given-names></name><article-title>Dissecting Fragment-Based
Lead Discovery at the von Hippel-Lindau Protein:Hypoxia Inducible
Factor 1α Protein-Protein Interface</article-title>. <source>Chem.
Biol.</source><year>2012</year>, <volume>19</volume>, <fpage>1300</fpage>–<lpage>1312</lpage>. <pub-id pub-id-type="doi">10.1016/j.chembiol.2012.08.015</pub-id>.<pub-id pub-id-type="pmid">23102223</pub-id></mixed-citation>
    </ref>
    <ref id="ref14">
      <mixed-citation publication-type="journal" id="cit14"><name><surname>Galdeano</surname><given-names>C.</given-names></name>; <name><surname>Gadd</surname><given-names>M. S.</given-names></name>; <name><surname>Soares</surname><given-names>P.</given-names></name>; <name><surname>Scaffidi</surname><given-names>S.</given-names></name>; <name><surname>Van Molle</surname><given-names>I.</given-names></name>; <name><surname>Birced</surname><given-names>I.</given-names></name>; <name><surname>Hewitt</surname><given-names>S.</given-names></name>; <name><surname>Dias</surname><given-names>D. M.</given-names></name>; <name><surname>Ciulli</surname><given-names>A.</given-names></name><article-title>Structure-Guided
Design and Optimization of Small Molecules Targeting the Protein–Protein
Interaction between the von Hippel–Lindau (VHL) E3 Ubiquitin
Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in
Vitro Nanomolar Affinities</article-title>. <source>J. Med. Chem.</source><year>2014</year>, <volume>57</volume>, <fpage>8657</fpage>–<lpage>8663</lpage>. <pub-id pub-id-type="doi">10.1021/jm5011258</pub-id>.<pub-id pub-id-type="pmid">25166285</pub-id></mixed-citation>
    </ref>
    <ref id="ref15">
      <mixed-citation publication-type="journal" id="cit15"><name><surname>Lohbeck</surname><given-names>J.</given-names></name>; <name><surname>Miller</surname><given-names>A. K.</given-names></name><article-title>Practical Synthesis
of a Phthalimide-Based Cereblon
Ligand to Enable PROTAC Development</article-title>. <source>Bioorg.
Med. Chem. Lett.</source><year>2016</year>, <volume>26</volume>, <fpage>5260</fpage>–<lpage>5262</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2016.09.048</pub-id>.<pub-id pub-id-type="pmid">27687673</pub-id></mixed-citation>
    </ref>
    <ref id="ref16">
      <mixed-citation publication-type="journal" id="cit16"><name><surname>Krajcovicova</surname><given-names>S.</given-names></name>; <name><surname>Jorda</surname><given-names>R.</given-names></name>; <name><surname>Hendrychova</surname><given-names>D.</given-names></name>; <name><surname>Krystof</surname><given-names>V.</given-names></name>; <name><surname>Soural</surname><given-names>M.</given-names></name><article-title>Solid-Phase
Synthesis for Thalidomide-Based Proteolysis-Targeting Chimeras (PROTAC)</article-title>. <source>Chem. Commun.</source><year>2019</year>, <volume>55</volume>, <fpage>929</fpage>–<lpage>932</lpage>. <pub-id pub-id-type="doi">10.1039/C8CC08716D</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref17">
      <mixed-citation publication-type="journal" id="cit17"><name><surname>Lai</surname><given-names>A. C.</given-names></name>; <name><surname>Toure</surname><given-names>M.</given-names></name>; <name><surname>Hellerschmied</surname><given-names>D.</given-names></name>; <name><surname>Salami</surname><given-names>J.</given-names></name>; <name><surname>Jaime-Figueroa</surname><given-names>S.</given-names></name>; <name><surname>Ko</surname><given-names>E.</given-names></name>; <name><surname>Hines</surname><given-names>J.</given-names></name>; <name><surname>Crews</surname><given-names>C. M.</given-names></name><article-title>Modular PROTAC Design for the Degradation
of Oncogenic BCR-ABL</article-title>. <source>Angew. Chem., Int. Ed.</source><year>2016</year>, <volume>55</volume>, <fpage>807</fpage>–<lpage>810</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201507634</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref18">
      <mixed-citation publication-type="journal" id="cit18"><name><surname>Cyrus</surname><given-names>K.</given-names></name>; <name><surname>Wehenkel</surname><given-names>M.</given-names></name>; <name><surname>Choi</surname><given-names>E.-Y.</given-names></name>; <name><surname>Lee</surname><given-names>H.</given-names></name>; <name><surname>Swanson</surname><given-names>H.</given-names></name>; <name><surname>Kim</surname><given-names>K.-B.</given-names></name><article-title>Jostling for Position: Optimizing
Linker Location in
the Design of Estrogen Receptor-Targeting PROTACs</article-title>. <source>ChemMedChem</source><year>2010</year>, <volume>5</volume>, <fpage>979</fpage>–<lpage>985</lpage>. <pub-id pub-id-type="doi">10.1002/cmdc.201000146</pub-id>.<pub-id pub-id-type="pmid">20512796</pub-id></mixed-citation>
    </ref>
    <ref id="ref19">
      <mixed-citation publication-type="journal" id="cit19"><name><surname>Zeng</surname><given-names>M.</given-names></name>; <name><surname>Xiong</surname><given-names>Y.</given-names></name>; <name><surname>Safaee</surname><given-names>N.</given-names></name>; <name><surname>Nowak</surname><given-names>R. P.</given-names></name>; <name><surname>Donovan</surname><given-names>K. A.</given-names></name>; <name><surname>Yuan</surname><given-names>C. J.</given-names></name>; <name><surname>Nabet</surname><given-names>B.</given-names></name>; <name><surname>Gero</surname><given-names>T. W.</given-names></name>; <name><surname>Feru</surname><given-names>F.</given-names></name>; <name><surname>Li</surname><given-names>L.</given-names></name>; <name><surname>Gondi</surname><given-names>S.</given-names></name>; <name><surname>Ombelets</surname><given-names>L. J.</given-names></name>; <name><surname>Quan</surname><given-names>C.</given-names></name>; <name><surname>Jänne</surname><given-names>P. A.</given-names></name>; <name><surname>Kostic</surname><given-names>M.</given-names></name>; <name><surname>Scott</surname><given-names>D. A.</given-names></name>; <name><surname>Westover</surname><given-names>K. D.</given-names></name>; <name><surname>Fischer</surname><given-names>E. S.</given-names></name>; <name><surname>Gray</surname><given-names>N. S.</given-names></name><article-title>Exploring Targeted Degradation Strategy for Oncogenic
KRASG12C</article-title>. <source>Cell Chem. Biol.</source><year>2020</year>, <volume>27</volume>, <fpage>19</fpage>–<lpage>31</lpage>. <comment>e6</comment><pub-id pub-id-type="doi">10.1016/j.chembiol.2019.12.006</pub-id>.<pub-id pub-id-type="pmid">31883964</pub-id></mixed-citation>
    </ref>
    <ref id="ref20">
      <mixed-citation publication-type="journal" id="cit20"><name><surname>Zorba</surname><given-names>A.</given-names></name>; <name><surname>Nguyen</surname><given-names>C.</given-names></name>; <name><surname>Xu</surname><given-names>Y.</given-names></name>; <name><surname>Starr</surname><given-names>J.</given-names></name>; <name><surname>Borzilleri</surname><given-names>K.</given-names></name>; <name><surname>Smith</surname><given-names>J.</given-names></name>; <name><surname>Zhu</surname><given-names>H.</given-names></name>; <name><surname>Farley</surname><given-names>K. A.</given-names></name>; <name><surname>Ding</surname><given-names>W.</given-names></name>; <name><surname>Schiemer</surname><given-names>J.</given-names></name>; <name><surname>Feng</surname><given-names>X.</given-names></name>; <name><surname>Chang</surname><given-names>J. S.</given-names></name>; <name><surname>Uccello</surname><given-names>D. P.</given-names></name>; <name><surname>Young</surname><given-names>J. A.</given-names></name>; <name><surname>Garcia-Irrizary</surname><given-names>C. N.</given-names></name>; <name><surname>Czabaniuk</surname><given-names>L.</given-names></name>; <name><surname>Schuff</surname><given-names>B.</given-names></name>; <name><surname>Oliver</surname><given-names>R.</given-names></name>; <name><surname>Montgomery</surname><given-names>J.</given-names></name>; <name><surname>Hayward</surname><given-names>M. M.</given-names></name>; <name><surname>Coe</surname><given-names>J.</given-names></name>; <name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Niosi</surname><given-names>M.</given-names></name>; <name><surname>Luthra</surname><given-names>S.</given-names></name>; <name><surname>Shah</surname><given-names>J. C.</given-names></name>; <name><surname>El-Kattan</surname><given-names>A.</given-names></name>; <name><surname>Qiu</surname><given-names>X.</given-names></name>; <name><surname>West</surname><given-names>G. M.</given-names></name>; <name><surname>Noe</surname><given-names>M. C.</given-names></name>; <name><surname>Shanmugasundaram</surname><given-names>V.</given-names></name>; <name><surname>Gilbert</surname><given-names>A. M.</given-names></name>; <name><surname>Brown</surname><given-names>M. F.</given-names></name>; <name><surname>Calabrese</surname><given-names>M. F.</given-names></name><article-title>Delineating
the Role of Cooperativity in the Design of Potent PROTACs for BTK</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><year>2018</year>, <volume>115</volume>, <fpage>E7285</fpage>–<lpage>E7292</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1803662115</pub-id>.<pub-id pub-id-type="pmid">30012605</pub-id></mixed-citation>
    </ref>
    <ref id="ref21">
      <mixed-citation publication-type="journal" id="cit21"><name><surname>Hughes</surname><given-names>S. J.</given-names></name>; <name><surname>Ciulli</surname><given-names>A.</given-names></name><article-title>Molecular Recognition
of Ternary Complexes: A New Dimension
in the Structure-Guided Design of Chemical Degraders</article-title>. <source>Essays Biochem.</source><year>2017</year>, <volume>61</volume>, <fpage>505</fpage>–<lpage>516</lpage>. <pub-id pub-id-type="doi">10.1042/EBC20170041</pub-id>.<pub-id pub-id-type="pmid">29118097</pub-id></mixed-citation>
    </ref>
    <ref id="ref22">
      <mixed-citation publication-type="journal" id="cit22"><name><surname>Roy</surname><given-names>M. J.</given-names></name>; <name><surname>Winkler</surname><given-names>S.</given-names></name>; <name><surname>Hughes</surname><given-names>S. J.</given-names></name>; <name><surname>Whitworth</surname><given-names>C.</given-names></name>; <name><surname>Galant</surname><given-names>M.</given-names></name>; <name><surname>Farnaby</surname><given-names>W.</given-names></name>; <name><surname>Rumpel</surname><given-names>K.</given-names></name>; <name><surname>Ciulli</surname><given-names>A.</given-names></name><article-title>SPR-Measured
Dissociation Kinetics of PROTAC Ternary Complexes Influence Target
Degradation Rate</article-title>. <source>ACS Chem. Biol.</source><year>2019</year>, <volume>14</volume>, <fpage>361</fpage>–<lpage>368</lpage>. <pub-id pub-id-type="doi">10.1021/acschembio.9b00092</pub-id>.<pub-id pub-id-type="pmid">30721025</pub-id></mixed-citation>
    </ref>
    <ref id="ref23">
      <mixed-citation publication-type="journal" id="cit23"><name><surname>Drummond</surname><given-names>M. L.</given-names></name>; <name><surname>Williams</surname><given-names>C. I.</given-names></name><article-title>In Silico Modeling
of PROTAC-Mediated Ternary Complexes:
Validation and Application</article-title>. <source>J. Chem. Inf. Model.</source><year>2019</year>, <volume>59</volume>, <fpage>1634</fpage>–<lpage>1644</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.8b00872</pub-id>.<pub-id pub-id-type="pmid">30714732</pub-id></mixed-citation>
    </ref>
    <ref id="ref24">
      <mixed-citation publication-type="journal" id="cit24"><person-group person-group-type="allauthors"><name><surname>Drummond</surname><given-names>M. L.</given-names></name>; <name><surname>Henry</surname><given-names>A.</given-names></name>; <name><surname>Li</surname><given-names>H.</given-names></name>; <name><surname>Williams</surname><given-names>C. I.</given-names></name></person-group><article-title>Improved Accuracy for Modeling
PROTAC-Mediated Ternary Complex Formation and Targeted Protein Degradation
via New In Silico Methodologies</article-title>, <source>J. Chem.
Inf. Model.</source><year>2020</year>,<pub-id pub-id-type="doi">10.1021/acs.jcim.0c00897</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref25">
      <mixed-citation publication-type="journal" id="cit25"><person-group person-group-type="allauthors"><name><surname>Bai</surname><given-names>N.</given-names></name>; <name><surname>Kirubakaran</surname><given-names>P.</given-names></name>; <name><surname>Karanicolas</surname><given-names>J.</given-names></name></person-group><article-title>Rationalizing
PROTAC-Mediated Ternary Complex Formation Using Rosetta</article-title>, <source>bioRxiv</source><year>2020</year>,<pub-id pub-id-type="doi">10.1101/2020.05.27.119347</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref26">
      <mixed-citation publication-type="journal" id="cit26"><name><surname>Lebraud</surname><given-names>H.</given-names></name>; <name><surname>Wright</surname><given-names>D. J.</given-names></name>; <name><surname>Johnson</surname><given-names>C. N.</given-names></name>; <name><surname>Heightman</surname><given-names>T. D.</given-names></name><article-title>Protein
Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras</article-title>. <source>ACS Cent. Sci.</source><year>2016</year>, <volume>2</volume>, <fpage>927</fpage>–<lpage>934</lpage>. <pub-id pub-id-type="doi">10.1021/acscentsci.6b00280</pub-id>.<pub-id pub-id-type="pmid">28058282</pub-id></mixed-citation>
    </ref>
    <ref id="ref27">
      <mixed-citation publication-type="journal" id="cit27"><name><surname>van
Zundert</surname><given-names>G. C. P.</given-names></name>; <name><surname>Rodrigues</surname><given-names>J. P. G. L.
M.</given-names></name>; <name><surname>Trellet</surname><given-names>M.</given-names></name>; <name><surname>Schmitz</surname><given-names>C.</given-names></name>; <name><surname>Kastritis</surname><given-names>P. L.</given-names></name>; <name><surname>Karaca</surname><given-names>E.</given-names></name>; <name><surname>Melquiond</surname><given-names>A. S. J.</given-names></name>; <name><surname>van Dijk</surname><given-names>M.</given-names></name>; <name><surname>de Vries</surname><given-names>S. J.</given-names></name>; <name><surname>Bonvin</surname><given-names>A. M. J. J.</given-names></name><article-title>The HADDOCK2.2
Web Server: User-Friendly Integrative Modeling of Biomolecular Complexes</article-title>. <source>J. Mol. Biol.</source><year>2016</year>, <volume>428</volume>, <fpage>720</fpage>–<lpage>725</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2015.09.014</pub-id>.<pub-id pub-id-type="pmid">26410586</pub-id></mixed-citation>
    </ref>
    <ref id="ref28">
      <mixed-citation publication-type="journal" id="cit28"><name><surname>Schiedel</surname><given-names>M.</given-names></name>; <name><surname>Herp</surname><given-names>D.</given-names></name>; <name><surname>Hammelmann</surname><given-names>S.</given-names></name>; <name><surname>Swyter</surname><given-names>S.</given-names></name>; <name><surname>Lehotzky</surname><given-names>A.</given-names></name>; <name><surname>Robaa</surname><given-names>D.</given-names></name>; <name><surname>Oláh</surname><given-names>J.</given-names></name>; <name><surname>Ovádi</surname><given-names>J.</given-names></name>; <name><surname>Sippl</surname><given-names>W.</given-names></name>; <name><surname>Jung</surname><given-names>M.</given-names></name><article-title>Chemically Induced
Degradation of
Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based
on Sirtuin Rearranging Ligands (SirReals)</article-title>. <source>J.
Med. Chem.</source><year>2018</year>, <volume>61</volume>, <fpage>482</fpage>–<lpage>491</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b01872</pub-id>.<pub-id pub-id-type="pmid">28379698</pub-id></mixed-citation>
    </ref>
    <ref id="ref29">
      <mixed-citation publication-type="journal" id="cit29"><name><surname>Nowak</surname><given-names>R. P.</given-names></name>; <name><surname>DeAngelo</surname><given-names>S. L.</given-names></name>; <name><surname>Buckley</surname><given-names>D.</given-names></name>; <name><surname>He</surname><given-names>Z.</given-names></name>; <name><surname>Donovan</surname><given-names>K. A.</given-names></name>; <name><surname>An</surname><given-names>J.</given-names></name>; <name><surname>Safaee</surname><given-names>N.</given-names></name>; <name><surname>Jedrychowski</surname><given-names>M. P.</given-names></name>; <name><surname>Ponthier</surname><given-names>C. M.</given-names></name>; <name><surname>Ishoey</surname><given-names>M.</given-names></name>; <name><surname>Zhang</surname><given-names>T.</given-names></name>; <name><surname>Mancias</surname><given-names>J. D.</given-names></name>; <name><surname>Gray</surname><given-names>N. S.</given-names></name>; <name><surname>Bradner</surname><given-names>J. E.</given-names></name>; <name><surname>Fischer</surname><given-names>E. S.</given-names></name><article-title>Plasticity in Binding Confers Selectivity in Ligand-Induced
Protein Degradation</article-title>. <source>Nat. Chem. Biol.</source><year>2018</year>, <volume>14</volume>, <fpage>706</fpage>–<lpage>714</lpage>. <pub-id pub-id-type="doi">10.1038/s41589-018-0055-y</pub-id>.<pub-id pub-id-type="pmid">29892083</pub-id></mixed-citation>
    </ref>
    <ref id="ref30">
      <mixed-citation publication-type="journal" id="cit30"><name><surname>Testa</surname><given-names>A.</given-names></name>; <name><surname>Hughes</surname><given-names>S. J.</given-names></name>; <name><surname>Lucas</surname><given-names>X.</given-names></name>; <name><surname>Wright</surname><given-names>J. E.</given-names></name>; <name><surname>Ciulli</surname><given-names>A.</given-names></name><article-title>Structure-Based
Design of a Macrocyclic PROTAC</article-title>. <source>Angew. Chem.,
Int. Ed.</source><year>2020</year>, <volume>59</volume>, <fpage>1727</fpage>–<lpage>1734</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201914396</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref31">
      <mixed-citation publication-type="journal" id="cit31"><name><surname>Pérez-Benito</surname><given-names>L.</given-names></name>; <name><surname>Henry</surname><given-names>A.</given-names></name>; <name><surname>Matsoukas</surname><given-names>M.-T.</given-names></name>; <name><surname>Lopez</surname><given-names>L.</given-names></name>; <name><surname>Pulido</surname><given-names>D.</given-names></name>; <name><surname>Royo</surname><given-names>M.</given-names></name>; <name><surname>Cordomí</surname><given-names>A.</given-names></name>; <name><surname>Tresadern</surname><given-names>G.</given-names></name>; <name><surname>Pardo</surname><given-names>L.</given-names></name><article-title>The Size Matters? A Computational Tool to Design Bivalent Ligands</article-title>. <source>Bioinformatics</source><year>2018</year>, <volume>34</volume>, <fpage>3857</fpage>–<lpage>3863</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/bty422</pub-id>.<pub-id pub-id-type="pmid">29850769</pub-id></mixed-citation>
    </ref>
    <ref id="ref32">
      <mixed-citation publication-type="journal" id="cit32"><name><surname>Imrie</surname><given-names>F.</given-names></name>; <name><surname>Bradley</surname><given-names>A. R.</given-names></name>; <name><surname>van der Schaar</surname><given-names>M.</given-names></name>; <name><surname>Deane</surname><given-names>C. M.</given-names></name><article-title>Deep Generative
Models for 3D Linker Design</article-title>. <source>J. Chem. Inf. Model.</source><year>2020</year>, <volume>60</volume>, <fpage>1983</fpage><pub-id pub-id-type="doi">10.1021/acs.jcim.9b01120</pub-id>.<pub-id pub-id-type="pmid">32195587</pub-id></mixed-citation>
    </ref>
    <ref id="ref33">
      <mixed-citation publication-type="book" id="cit33"><person-group person-group-type="allauthors"><name><surname>Duhovny</surname><given-names>D.</given-names></name>; <name><surname>Nussinov</surname><given-names>R.</given-names></name>; <name><surname>Wolfson</surname><given-names>H. J.</given-names></name></person-group><article-title>Efficient Unbound
Docking of Rigid Molecules</article-title>. In <source>Algorithms
in Bioinformatics</source>; <publisher-name>Springer</publisher-name>: <publisher-loc>Berlin</publisher-loc>, <year>2002</year>; pp <fpage>185</fpage>–<lpage>200</lpage>.</mixed-citation>
    </ref>
    <ref id="ref34">
      <mixed-citation publication-type="journal" id="cit34"><name><surname>Schneidman-Duhovny</surname><given-names>D.</given-names></name>; <name><surname>Inbar</surname><given-names>Y.</given-names></name>; <name><surname>Nussinov</surname><given-names>R.</given-names></name>; <name><surname>Wolfson</surname><given-names>H. J.</given-names></name><article-title>PatchDock and SymmDock:
Servers for Rigid and Symmetric Docking</article-title>. <source>Nucleic
Acids Res.</source><year>2005</year>, <volume>33</volume>, <fpage>W363</fpage>–<lpage>W367</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gki481</pub-id>.<pub-id pub-id-type="pmid">15980490</pub-id></mixed-citation>
    </ref>
    <ref id="ref35">
      <mixed-citation publication-type="journal" id="cit35"><name><surname>Gray</surname><given-names>J. J.</given-names></name>; <name><surname>Moughon</surname><given-names>S.</given-names></name>; <name><surname>Wang</surname><given-names>C.</given-names></name>; <name><surname>Schueler-Furman</surname><given-names>O.</given-names></name>; <name><surname>Kuhlman</surname><given-names>B.</given-names></name>; <name><surname>Rohl</surname><given-names>C. A.</given-names></name>; <name><surname>Baker</surname><given-names>D.</given-names></name><article-title>Protein–Protein
Docking with Simultaneous Optimization of Rigid-Body Displacement
and Side-Chain Conformations</article-title>. <source>J. Mol. Biol.</source><year>2003</year>, <volume>331</volume>, <fpage>281</fpage>–<lpage>299</lpage>. <pub-id pub-id-type="doi">10.1016/S0022-2836(03)00670-3</pub-id>.<pub-id pub-id-type="pmid">12875852</pub-id></mixed-citation>
    </ref>
    <ref id="ref36">
      <mixed-citation publication-type="journal" id="cit36"><name><surname>Leaver-Fay</surname><given-names>A.</given-names></name>; <name><surname>Tyka</surname><given-names>M.</given-names></name>; <name><surname>Lewis</surname><given-names>S. M.</given-names></name>; <name><surname>Lange</surname><given-names>O. F.</given-names></name>; <name><surname>Thompson</surname><given-names>J.</given-names></name>; <name><surname>Jacak</surname><given-names>R.</given-names></name>; <name><surname>Kaufman</surname><given-names>K.</given-names></name>; <name><surname>Renfrew</surname><given-names>P. D.</given-names></name>; <name><surname>Smith</surname><given-names>C. A.</given-names></name>; <name><surname>Sheffler</surname><given-names>W.</given-names></name>; <name><surname>Davis</surname><given-names>I. W.</given-names></name>; <name><surname>Cooper</surname><given-names>S.</given-names></name>; <name><surname>Treuille</surname><given-names>A.</given-names></name>; <name><surname>Mandell</surname><given-names>D. J.</given-names></name>; <name><surname>Richter</surname><given-names>F.</given-names></name>; <name><surname>Ban</surname><given-names>Y.-E. A.</given-names></name>; <name><surname>Fleishman</surname><given-names>S. J.</given-names></name>; <name><surname>Corn</surname><given-names>J. E.</given-names></name>; <name><surname>Kim</surname><given-names>D. E.</given-names></name>; <name><surname>Lyskov</surname><given-names>S.</given-names></name>; <name><surname>Berrondo</surname><given-names>M.</given-names></name>; <name><surname>Mentzer</surname><given-names>S.</given-names></name>; <name><surname>Popović</surname><given-names>Z.</given-names></name>; <name><surname>Havranek</surname><given-names>J. J.</given-names></name>; <name><surname>Karanicolas</surname><given-names>J.</given-names></name>; <name><surname>Das</surname><given-names>R.</given-names></name>; <name><surname>Meiler</surname><given-names>J.</given-names></name>; <name><surname>Kortemme</surname><given-names>T.</given-names></name>; <name><surname>Gray</surname><given-names>J. J.</given-names></name>; <name><surname>Kuhlman</surname><given-names>B.</given-names></name>; <name><surname>Baker</surname><given-names>D.</given-names></name>; <name><surname>Bradley</surname><given-names>P.</given-names></name><article-title>ROSETTA3: An Object-Oriented Software
Suite for the Simulation and Design of Macromolecules</article-title>. <source>Methods Enzymol.</source><year>2011</year>, <volume>487</volume>, <fpage>545</fpage>–<lpage>574</lpage>. <pub-id pub-id-type="doi">10.1016/B978-0-12-381270-4.00019-6</pub-id>.<pub-id pub-id-type="pmid">21187238</pub-id></mixed-citation>
    </ref>
    <ref id="ref37">
      <mixed-citation publication-type="journal" id="cit37"><name><surname>Lyskov</surname><given-names>S.</given-names></name>; <name><surname>Gray</surname><given-names>J. J.</given-names></name><article-title>The RosettaDock
Server for Local Protein–protein
Docking</article-title>. <source>Nucleic Acids Res.</source><year>2008</year>, <volume>36</volume>, <fpage>W233</fpage>–<lpage>W238</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkn216</pub-id>.<pub-id pub-id-type="pmid">18442991</pub-id></mixed-citation>
    </ref>
    <ref id="ref38">
      <mixed-citation publication-type="journal" id="cit38"><name><surname>Kuhlman</surname><given-names>B.</given-names></name>; <name><surname>Baker</surname><given-names>D.</given-names></name><article-title>Native Protein Sequences
Are close to Optimal for Their Structures</article-title>. <source>Proc.
Natl. Acad. Sci. U. S. A.</source><year>2000</year>, <volume>97</volume>, <fpage>10383</fpage>–<lpage>10388</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.97.19.10383</pub-id>.<pub-id pub-id-type="pmid">10984534</pub-id></mixed-citation>
    </ref>
    <ref id="ref39">
      <mixed-citation publication-type="journal" id="cit39"><name><surname>Ester</surname><given-names>M.</given-names></name>; <name><surname>Kriegel</surname><given-names>H.-P.</given-names></name>; <name><surname>Sander</surname><given-names>J.</given-names></name>; <name><surname>Xu</surname><given-names>X.</given-names></name><article-title>A Density-Based
Algorithm
for Discovering Clusters in Large Spatial Databases with Noise</article-title>. <source>In Kdd</source><year>1996</year>, <volume>96</volume>, <fpage>226</fpage>–<lpage>231</lpage>.</mixed-citation>
    </ref>
    <ref id="ref40">
      <mixed-citation publication-type="journal" id="cit40"><name><surname>Lensink</surname><given-names>M. F.</given-names></name>; <name><surname>Méndez</surname><given-names>R.</given-names></name>; <name><surname>Wodak</surname><given-names>S. J.</given-names></name><article-title>Docking and Scoring Protein Complexes:
CAPRI 3rd ed</article-title>. <source>Proteins</source><year>2007</year>, <volume>69</volume>, <fpage>704</fpage>–<lpage>718</lpage>.<pub-id pub-id-type="pmid">17918726</pub-id></mixed-citation>
    </ref>
    <ref id="ref41">
      <mixed-citation publication-type="journal" id="cit41"><name><surname>Tina</surname><given-names>K. G.</given-names></name>; <name><surname>Bhadra</surname><given-names>R.</given-names></name>; <name><surname>Srinivasan</surname><given-names>N.</given-names></name><article-title>PIC: Protein
Interactions Calculator</article-title>. <source>Nucleic Acids Res.</source><year>2007</year>, <volume>35</volume>, <fpage>W473</fpage>–<lpage>W476</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkm423</pub-id>.<pub-id pub-id-type="pmid">17584791</pub-id></mixed-citation>
    </ref>
    <ref id="ref42">
      <mixed-citation publication-type="journal" id="cit42"><name><surname>Farnaby</surname><given-names>W.</given-names></name>; <name><surname>Koegl</surname><given-names>M.</given-names></name>; <name><surname>Roy</surname><given-names>M. J.</given-names></name>; <name><surname>Whitworth</surname><given-names>C.</given-names></name>; <name><surname>Diers</surname><given-names>E.</given-names></name>; <name><surname>Trainor</surname><given-names>N.</given-names></name>; <name><surname>Zollman</surname><given-names>D.</given-names></name>; <name><surname>Steurer</surname><given-names>S.</given-names></name>; <name><surname>Karolyi-Oezguer</surname><given-names>J.</given-names></name>; <name><surname>Riedmueller</surname><given-names>C.</given-names></name>; <name><surname>Gmaschitz</surname><given-names>T.</given-names></name>; <name><surname>Wachter</surname><given-names>J.</given-names></name>; <name><surname>Dank</surname><given-names>C.</given-names></name>; <name><surname>Galant</surname><given-names>M.</given-names></name>; <name><surname>Sharps</surname><given-names>B.</given-names></name>; <name><surname>Rumpel</surname><given-names>K.</given-names></name>; <name><surname>Traxler</surname><given-names>E.</given-names></name>; <name><surname>Gerstberger</surname><given-names>T.</given-names></name>; <name><surname>Schnitzer</surname><given-names>R.</given-names></name>; <name><surname>Petermann</surname><given-names>O.</given-names></name>; <name><surname>Greb</surname><given-names>P.</given-names></name>; <name><surname>Weinstabl</surname><given-names>H.</given-names></name>; <name><surname>Bader</surname><given-names>G.</given-names></name>; <name><surname>Zoephel</surname><given-names>A.</given-names></name>; <name><surname>Weiss-Puxbaum</surname><given-names>A.</given-names></name>; <name><surname>Ehrenhöfer-Wölfer</surname><given-names>K.</given-names></name>; <name><surname>Wöhrle</surname><given-names>S.</given-names></name>; <name><surname>Boehmelt</surname><given-names>G.</given-names></name>; <name><surname>Rinnenthal</surname><given-names>J.</given-names></name>; <name><surname>Arnhof</surname><given-names>H.</given-names></name>; <name><surname>Wiechens</surname><given-names>N.</given-names></name>; <name><surname>Wu</surname><given-names>M.-Y.</given-names></name>; <name><surname>Owen-Hughes</surname><given-names>T.</given-names></name>; <name><surname>Ettmayer</surname><given-names>P.</given-names></name>; <name><surname>Pearson</surname><given-names>M.</given-names></name>; <name><surname>McConnell</surname><given-names>D. B.</given-names></name>; <name><surname>Ciulli</surname><given-names>A.</given-names></name><article-title>BAF Complex Vulnerabilities in Cancer
Demonstrated via Structure-Based PROTAC Design</article-title>. <source>Nat. Chem. Biol.</source><year>2019</year>, <volume>15</volume>, <fpage>672</fpage>–<lpage>680</lpage>. <pub-id pub-id-type="doi">10.1038/s41589-019-0294-6</pub-id>.<pub-id pub-id-type="pmid">31178587</pub-id></mixed-citation>
    </ref>
    <ref id="ref43">
      <mixed-citation publication-type="journal" id="cit43"><name><surname>Neklesa</surname><given-names>T.</given-names></name>; <name><surname>Snyder</surname><given-names>L. B.</given-names></name>; <name><surname>Willard</surname><given-names>R. R.</given-names></name>; <name><surname>Vitale</surname><given-names>N.</given-names></name>; <name><surname>Pizzano</surname><given-names>J.</given-names></name>; <name><surname>Gordon</surname><given-names>D. A.</given-names></name>; <name><surname>Bookbinder</surname><given-names>M.</given-names></name>; <name><surname>Macaluso</surname><given-names>J.</given-names></name>; <name><surname>Dong</surname><given-names>H.</given-names></name>; <name><surname>Ferraro</surname><given-names>C.</given-names></name>; <name><surname>Wang</surname><given-names>G.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Crews</surname><given-names>C. M.</given-names></name>; <name><surname>Houston</surname><given-names>J.</given-names></name>; <name><surname>Crew</surname><given-names>A. P.</given-names></name>; <name><surname>Taylor</surname><given-names>I.</given-names></name><article-title>ARV-110: An Oral Androgen
Receptor PROTAC Degrader for Prostate Cancer</article-title>. <source>J. Clin. Oncol.</source><year>2019</year>, <volume>37</volume>, <fpage>259</fpage>–<lpage>259</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2019.37.7_suppl.259</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref44">
      <mixed-citation publication-type="journal" id="cit44"><name><surname>Daniels</surname><given-names>D. L.</given-names></name>; <name><surname>Riching</surname><given-names>K. M.</given-names></name>; <name><surname>Urh</surname><given-names>M.</given-names></name><article-title>Monitoring
and Deciphering Protein
Degradation Pathways inside Cells</article-title>. <source>Drug Discovery
Today: Technol.</source><year>2019</year>, <volume>31</volume>, <fpage>61</fpage>–<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1016/j.ddtec.2018.12.001</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref45">
      <mixed-citation publication-type="journal" id="cit45"><name><surname>Riching</surname><given-names>K. M.</given-names></name>; <name><surname>Mahan</surname><given-names>S.</given-names></name>; <name><surname>Corona</surname><given-names>C. R.</given-names></name>; <name><surname>McDougall</surname><given-names>M.</given-names></name>; <name><surname>Vasta</surname><given-names>J. D.</given-names></name>; <name><surname>Robers</surname><given-names>M. B.</given-names></name>; <name><surname>Urh</surname><given-names>M.</given-names></name>; <name><surname>Daniels</surname><given-names>D. L.</given-names></name><article-title>Quantitative
Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC
Mode of Action</article-title>. <source>ACS Chem. Biol.</source><year>2018</year>, <volume>13</volume>, <fpage>2758</fpage>–<lpage>2770</lpage>. <pub-id pub-id-type="doi">10.1021/acschembio.8b00692</pub-id>.<pub-id pub-id-type="pmid">30137962</pub-id></mixed-citation>
    </ref>
    <ref id="ref46">
      <mixed-citation publication-type="journal" id="cit46"><name><surname>Cromm</surname><given-names>P. M.</given-names></name>; <name><surname>Crews</surname><given-names>C. M.</given-names></name><article-title>Targeted Protein
Degradation: From Chemical Biology
to Drug Discovery</article-title>. <source>Cell Chem. Biol.</source><year>2017</year>, <volume>24</volume>, <fpage>1181</fpage>–<lpage>1190</lpage>. <pub-id pub-id-type="doi">10.1016/j.chembiol.2017.05.024</pub-id>.<pub-id pub-id-type="pmid">28648379</pub-id></mixed-citation>
    </ref>
    <ref id="ref47">
      <mixed-citation publication-type="journal" id="cit47"><name><surname>Pons</surname><given-names>C.</given-names></name>; <name><surname>Grosdidier</surname><given-names>S.</given-names></name>; <name><surname>Solernou</surname><given-names>A.</given-names></name>; <name><surname>Pérez-Cano</surname><given-names>L.</given-names></name>; <name><surname>Fernández-Recio</surname><given-names>J.</given-names></name><article-title>Present and
Future Challenges and
Limitations in Protein-Protein Docking</article-title>. <source>Proteins:
Struct., Funct., Genet.</source><year>2010</year>, <volume>78</volume>, <fpage>95</fpage>–<lpage>108</lpage>. <pub-id pub-id-type="doi">10.1002/prot.22564</pub-id>.<pub-id pub-id-type="pmid">19731373</pub-id></mixed-citation>
    </ref>
    <ref id="ref48">
      <mixed-citation publication-type="journal" id="cit48"><name><surname>Marze</surname><given-names>N. A.</given-names></name>; <name><surname>Roy Burman</surname><given-names>S. S.</given-names></name>; <name><surname>Sheffler</surname><given-names>W.</given-names></name>; <name><surname>Gray</surname><given-names>J. J.</given-names></name><article-title>Efficient Flexible
Backbone Protein–protein Docking for Challenging Targets</article-title>. <source>Bioinformatics</source><year>2018</year>, <volume>34</volume>, <fpage>3461</fpage>–<lpage>3469</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/bty355</pub-id>.<pub-id pub-id-type="pmid">29718115</pub-id></mixed-citation>
    </ref>
    <ref id="ref49">
      <mixed-citation publication-type="journal" id="cit49"><name><surname>Kuroda</surname><given-names>D.</given-names></name>; <name><surname>Gray</surname><given-names>J. J.</given-names></name><article-title>Pushing the Backbone in Protein-Protein
Docking</article-title>. <source>Structure</source><year>2016</year>, <volume>24</volume>, <fpage>1821</fpage>–<lpage>1829</lpage>. <pub-id pub-id-type="doi">10.1016/j.str.2016.06.025</pub-id>.<pub-id pub-id-type="pmid">27568930</pub-id></mixed-citation>
    </ref>
    <ref id="ref50">
      <mixed-citation publication-type="journal" id="cit50"><name><surname>Mashiach</surname><given-names>E.</given-names></name>; <name><surname>Nussinov</surname><given-names>R.</given-names></name>; <name><surname>Wolfson</surname><given-names>H. J.</given-names></name><article-title>FiberDock:
Flexible Induced-Fit Backbone
Refinement in Molecular Docking</article-title>. <source>Proteins: Struct.,
Funct., Genet.</source><year>2010</year>, <volume>78</volume>, <fpage>1503</fpage>–<lpage>1519</lpage>. <pub-id pub-id-type="doi">10.1002/prot.22668</pub-id>.<pub-id pub-id-type="pmid">20077569</pub-id></mixed-citation>
    </ref>
    <ref id="ref51">
      <mixed-citation publication-type="journal" id="cit51"><name><surname>Wang</surname><given-names>C.</given-names></name>; <name><surname>Bradley</surname><given-names>P.</given-names></name>; <name><surname>Baker</surname><given-names>D.</given-names></name><article-title>Protein–Protein Docking with
Backbone Flexibility</article-title>. <source>J. Mol. Biol.</source><year>2007</year>, <volume>373</volume>, <fpage>503</fpage>–<lpage>519</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2007.07.050</pub-id>.<pub-id pub-id-type="pmid">17825317</pub-id></mixed-citation>
    </ref>
    <ref id="ref52">
      <mixed-citation publication-type="journal" id="cit52"><name><surname>Zacharias</surname><given-names>M.</given-names></name><article-title>Accounting
for Conformational Changes during Protein–protein Docking</article-title>. <source>Curr. Opin. Struct. Biol.</source><year>2010</year>, <volume>20</volume>, <fpage>180</fpage>–<lpage>186</lpage>. <pub-id pub-id-type="doi">10.1016/j.sbi.2010.02.001</pub-id>.<pub-id pub-id-type="pmid">20194014</pub-id></mixed-citation>
    </ref>
    <ref id="ref53">
      <mixed-citation publication-type="journal" id="cit53"><name><surname>Zhang</surname><given-names>Z.</given-names></name>; <name><surname>Ehmann</surname><given-names>U.</given-names></name>; <name><surname>Zacharias</surname><given-names>M.</given-names></name><article-title>Monte Carlo
Replica-Exchange Based
Ensemble Docking of Protein Conformations</article-title>. <source>Proteins:
Struct., Funct., Genet.</source><year>2017</year>, <volume>85</volume>, <fpage>924</fpage>–<lpage>937</lpage>. <pub-id pub-id-type="doi">10.1002/prot.25262</pub-id>.<pub-id pub-id-type="pmid">28168752</pub-id></mixed-citation>
    </ref>
    <ref id="ref54">
      <mixed-citation publication-type="journal" id="cit54"><name><surname>Kurkcuoglu</surname><given-names>Z.</given-names></name>; <name><surname>Bonvin</surname><given-names>A. M.</given-names></name><article-title>Pre-and Post-Docking Sampling of Conformational Changes
Using ClustENM and HADDOCK for Protein-Protein and Protein-DNA Systems</article-title>. <source>Proteins: Struct., Funct., Genet.</source><year>2020</year>, <volume>88</volume>, <fpage>292</fpage>–<lpage>306</lpage>. <pub-id pub-id-type="doi">10.1002/prot.25802</pub-id>.<pub-id pub-id-type="pmid">31441121</pub-id></mixed-citation>
    </ref>
    <ref id="ref55">
      <mixed-citation publication-type="journal" id="cit55"><name><surname>Bonvin</surname><given-names>A. M.</given-names></name><article-title>Flexible
Protein–protein Docking</article-title>. <source>Curr. Opin.
Struct. Biol.</source><year>2006</year>, <volume>16</volume>, <fpage>194</fpage>–<lpage>200</lpage>. <pub-id pub-id-type="doi">10.1016/j.sbi.2006.02.002</pub-id>.<pub-id pub-id-type="pmid">16488145</pub-id></mixed-citation>
    </ref>
    <ref id="ref56">
      <mixed-citation publication-type="journal" id="cit56"><name><surname>Torchala</surname><given-names>M.</given-names></name>; <name><surname>Moal</surname><given-names>I. H.</given-names></name>; <name><surname>Chaleil</surname><given-names>R. A. G.</given-names></name>; <name><surname>Fernandez-Recio</surname><given-names>J.</given-names></name>; <name><surname>Bates</surname><given-names>P. A.</given-names></name><article-title>SwarmDock: A Server for Flexible Protein–protein
Docking</article-title>. <source>Bioinformatics</source><year>2013</year>, <volume>29</volume>, <fpage>807</fpage>–<lpage>809</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btt038</pub-id>.<pub-id pub-id-type="pmid">23343604</pub-id></mixed-citation>
    </ref>
    <ref id="ref57">
      <mixed-citation publication-type="journal" id="cit57"><name><surname>Fleishman</surname><given-names>S. J.</given-names></name>; <name><surname>Leaver-Fay</surname><given-names>A.</given-names></name>; <name><surname>Corn</surname><given-names>J. E.</given-names></name>; <name><surname>Strauch</surname><given-names>E.-M.</given-names></name>; <name><surname>Khare</surname><given-names>S. D.</given-names></name>; <name><surname>Koga</surname><given-names>N.</given-names></name>; <name><surname>Ashworth</surname><given-names>J.</given-names></name>; <name><surname>Murphy</surname><given-names>P.</given-names></name>; <name><surname>Richter</surname><given-names>F.</given-names></name>; <name><surname>Lemmon</surname><given-names>G.</given-names></name>; <name><surname>Meiler</surname><given-names>J.</given-names></name>; <name><surname>Baker</surname><given-names>D.</given-names></name><article-title>RosettaScripts: A Scripting
Language Interface to the Rosetta Macromolecular Modeling Suite</article-title>. <source>PLoS One</source><year>2011</year>, <volume>6</volume>, <elocation-id>e20161</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0020161</pub-id>.<pub-id pub-id-type="pmid">21731610</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
